

CURRICULUM VITAE

Mei-Chin Hsieh, PhD, MSPH, ODS-C

Business Address:

Louisiana Tumor Registry/Epidemiology and Population Health Program,
School of Public Health, Louisiana State University Health Sciences Center
2020 Gravier St., 3rd Floor
New Orleans, LA 70112

Phone: (504) 568-5850

Fax: (504) 568-5800

E-mail: mhsieh@lsuhsc.edu

EDUCATION

BS	6/1987	Medical Technology	School of Medical Technology China Medical University (Former China Medical College) Taichung, Taiwan
MSPH	8/1998	Biostatistics	Department of Biostatistics School of Public Health and Tropical Medicine Tulane University, New Orleans, LA
PhD	5/2016	Biostatistics	Department of Biostatistics and Bioinformatics School of Public Health and Tropical Medicine Tulane University, New Orleans, LA

HONORS AND AWARDS

- The **second-place poster award** at NAACCR Summer Forum 2022 on the cancer research titled “Racial/Ethnic Disparities in COVID-19 Infection among Working-Age Women with Precancerous Cervical Lesion” June 14, 2022.
- Service award-Recognition certificate for service to the School of Public Health Faculty Assembly, LSUHSC-New Orleans, 2020-2021. Received on June 18, 2021.
- The **second-place poster award** at NAACCR Summer Forum 2021 on the cancer research titled “Do Modifiable Risk Factors Impact Pancreatic Cancer Survival in a Population-based Study after Adjusting for Clinical Factors?” June 17, 2021.

- Journal of Registry Management **Best Paper of the Year 2019** on the original article entitled “Evaluating the Use of LAST Two-tiered Nomenclature and Its Impact on Reporting Cervical Lesions in a Population-Based Cancer Registry.” Received on September 23rd 2020 at NCRA 46th Annual Educational Virtual Conference.
- Recognition certificate for service and contribution as a NAACCR committee member, 2018-2019. Received on August 18, 2019.
- Journal of Registry Management **Best Paper of the Year 2017 Honorable Mention** on the original article entitled “An Innovative Approach to Improve Completeness of Treatment and Other Key Data Elements in a Population-Based Cancer Registry: A 15-Month Data Submission”. Received on May 23rd 2018 at NCRA 44th Annual Educational Conference.
- Louisiana Cancer Registrars Association (LCRA) Jane Rodriguez Distinguished Member Award. October 13, 2016.
- North American Association of Central Cancer Registries (NAACCR) Leadership Award, June 15, 2016
- Journal of Registry Management **Best Paper of the Year 2012** on the original article entitled “Evaluating Factors Associated with Unknown SEER Summary Stage 2000 Derived from Collaborative Stage at Central Registry Level”, Received on June 2nd 2013 at NCRA 39th Annual Educational Conference.
- North American Association of Central Cancer Registries (NAACCR) Merit Award, June 2012
- North American Association of Central Cancer Registries (NAACCR) Achievement Award, June 2012
- The first place in Data Quality/Registry Operations and Management: NAACCR Annual Conference Poster Session, 2009: “*Incidence of Soft Tissue Sarcoma in Older Adolescents and Young Adults, United State, 1995 to 2004*”
- Recognition certificate for services and contributions as a member of Race and Ethnicity Work Group: North American Association of Central Cancer Registries (NAACCR), 2009
- Recognition certificate for services and contributions as a member of Asian/Pacific Islander Identification Panel: North American Association of Central Cancer Registries (NAACCR), 2004-2008
- Honorary Public Health Society: **Delta Omega Award** Eta Chapter (Tulane University), 1999

CERTIFICATIONS

3/2003 Oncology Data Specialist Certified (ODS-C): Former title Certified Tumor Registrar (CTR), National Cancer Registrars’ Association, USA.
ODS Number: 2003056

EMPLOYMENT

7/2021 – Present	Associate Professor-Research Epidemiology program, School of Public Health, Louisiana State University Health Sciences Center, New Orleans, LA
6/2016 – Present	Assistant Director Louisiana Tumor Registry/Epidemiology program, School of Public Health Louisiana State University Health Sciences Center, New Orleans, LA
6/2016 – 6/2021	Assistant Professor-Research Epidemiology program, School of Public Health, Louisiana State University Health Sciences Center, New Orleans, LA
1/2004 – 5/2016	Instructor-Research Epidemiology program, School of Public Health, Louisiana State University Health Sciences Center, New Orleans, LA
1/2004 – 5/2016	Central Data Manager Louisiana Tumor Registry/Epidemiology program, School of Public Health Louisiana State University Health Sciences Center, New Orleans, LA
7/2001 – 12/2003	Research Associate III (Senior Data Editor) Louisiana Tumor Registry, School of Public Health Louisiana State University Health Sciences Center, New Orleans, LA
1/2000 – 6/2001	Research Associate II (Data Editor) Louisiana Tumor Registry, Department of Public Health and Preventive Medicine, School of Medicine Louisiana State University Health Sciences Center, New Orleans, LA
3/1998 – 8/1998	Data Analyst (Internship) Department of Biostatistics Tulane University School of Public Health and Tropical Medicine
7/1995 – 1/1997	Medical Technologist Cytology Laboratory, Department of Internal Medicine, Cathay General Hospital, Taipei, Taiwan
5/1989 – 6/1995	Medical Technologist Laboratories of Clinical Chemistry, Blood Bank and Hematology, Department of Clinical Laboratory, Cathay General Hospital, Taipei, Taiwan
8/1987 – 5/1989	Medical Technologist Laboratories of Clinical Chemistry, Blood Bank, and Serology, Department of Clinical Laboratory, China Medical College Affiliated Peikang Hospital, Peikang, Taiwan

MEMBERSHIP IN PROFESSIONAL ORGANIZATIONS

3/2023 – present	Louisiana Public Health Association (LPHA)
3/2003 – present	National Cancer Registrars Association (NCRA)
2001 – present	Louisiana Cancer Registrars Association (LCRA)

APPOINTMENTS AND COMMITTEES

LSUHSC School of Public Health

7/2017 – 6/2019	Grievance Committee
7/2022 – 6/2024	APT Committee (Pointed by program chair)
7/2024 – 6/2026	APT Committee (Pointed by program chair)
7/2023 – 6/2025	Grievance Committee
7/2023 – 6/2026	Faculty Senate

Epidemiology & Population Health Program:

6/2022 – present	Graduate Coordinator, Epidemiology and Population Health Program
5/2025-4/2025	2025 EPPH PhD Qualifying Exam Committee

LSUHSC

11/2024 – 10/2025	Faculty Appeals Committee (Alternate member): nominated by Chancellor Dr. Steve Nelson
-------------------	--

Cancer Related Organizations**North American Association of Central Cancer Registries (NAACCR)**

9/2024 – present	CINA writing network workgroup
9/2022 – present	National Childhood Cancer Registries (NCCR) Data Products Workgroup
2020 – present	Rare cancer workgroup
5/2018 – 6/2022	Geocoder Technical Workgroup (a subgroup under the Research and Data Use Steering Committee)
2018 – present	NAACCR CINA Editorial Work Group
1/2019 – present	CiNA Statistics Work Group
1/2019 – 1/2025	NAACCR Site Specific Data Item Work Group
5/2017 – 4/2024	NAACCR IRB Board
2015 – present	NAACCR Research Application Review Workgroup
2012 – 2015	NAACCR Data Item Consolidation Work Group
5/2018 – 6/2022	NAACCR Data Assessment and Fitness for Use Workgroup (a subgroup under the Research and Data Use Steering Committee), Chair
1/2009 – 4/2018	NAACCR Data Assessment Workgroup (Changed to Data Assessment and Fitness for Use Workgroup), member
2003 – 2009	NAACCR Race and Ethnicity Work Group <ul style="list-style-type: none"> ▪ Asian/Pacific Islander identification Panel ▪ Latino Research Work Group

NCI Surveillance, Epidemiology, and End Results (SEER)

2024-present	National Childhood Cancer Registry (NCCR) Data Access Committee (DAC)
2018 – present	SEER Quality Improvement Experts (QIE) Panel
2018 – present	SEER/IMS SEER*DMS Claims Data Workgroup
2017 – present	SEER/IMS SEER*DMS Auto-Consolidation Working Group
2016-present	SEER PI Meeting
2016-present	SEER Research Call

2014-present SEER Manager Meeting

2014-present SEER SEER*DMS CCAB Meeting

2012 – 2014 ACS/CDC/NCI-SEER Collaborative Staging Data Elements Review Work Group

2010 – 2018 SEER Multiple Primary and Histology Rules Task Force, Lung Chapter

CDC-NPCR Cancer Surveillance Meetings

2016-present CDC-NPCR Town Hall meeting

2020-present CDC-NPCR bimonthly check-in meeting

Cancer Research Special Workgroup

2021 – present Transplant Cancer Match (TCM) Study Workgroup

RESPONSIBILITIES, EXPERIENCE, AND SKILLS

Cancer Surveillance:

- Manage the statewide tumor registry database and oversee the data management and data quality teams to ensure that the LTR complies with state and federal cancer reporting requirements for the data collection and providing high-quality cancer data.
 - Develop strategies and implementing procedures to process registry data in an efficient and timely manner.
 - Oversee all LTR QC activities including quality assessment on new data items, casefinding audit, re-abstraction audit, re-coding audit, and finding areas that needed more training.
 - Maintain high quality data to meet the national certification standards and funding agencies [NCI's Surveillance, Epidemiology and End Results Program (SEER) and CDC's National Program of Cancer Registries (NPCR)] requirements which include data completeness, timeliness, and high quality on key data items.
 - Coordinate data processing activities with regional registries and overseeing the completeness and timeliness of their data submissions.
 - Prepare and update the LTR procedure related to data management and data process.
 - Develop in-house (SAS) programs for data editing, processing, and QC checking and monitoring as needed.
 - Oversee data exchange activities with other states including sending non-Louisiana cases to other states twice a year and monitoring Louisiana resident cases diagnosed and/or treated in other states are transmitted to LTR in the timely manner.
 - Oversee the multiple annual data submissions to ensure funding agencies' requirements and specifications were met as well as to other national and international cancer surveillance programs for publication such as NCI-SEER National Longitudinal Mortality Study, SEER Medicare, and CONCORD study.
 - In charge the processing of LTR data migration: CNExT to RMCDS started in August 2003 and completed in June 2005 and RMCDS to SEER*DMS in Started in August 2007 and completed in February 2009

- Prepare proposals and budget for grant applications and prepare the progress and final reports.
- Assist the Director in preparing the progress report for NCI-SEER and CDC-NPCR.
- Collaborate with cancer research investigators and clinicians and provide assistance including data analysis in support of epidemiologic and clinical studies that use LTR data for research.
- Oversee all activities for the CIN3 project including completeness of data collection and data quality.
- Participate in NCI-SEER and CDC special projects as needed.
- cancer incidence and mortality rates for the LTR's monograph as needed.

Research

- Serve as a PI or co-investigator for federal funded research projects.
- Collaborate with LSUHSC or non-LSUHSC PIs for grant applications.
- Lead and collaborate with researchers for writing the scientific manuscripts

Statistical and Computer Skills:

- Proficient in statistical packages of SAS, SEER*Stat
- Proficient in registry software systems and cancer edit software such as Rocky Mountain Cancer Data System (RMCDs), SEER*DMS, SEER*Edits, and GenEDITS Plus, and Inter-Record Edits
- Proficient in SQL and MS Excel and Access
- Strong statistical and analytic skills, including the use of linear regression, logistic regression, ANOVA, survival analysis and multilevel analysis
- Knowledgeable of geographic information system related software, including ArcGIS, SaTScan and GeoDa

Administration and Supervision:

- Assist the LTR's Director in preparing grant applications, annual progress reports, and contract deliverables for the CDC-NPCR and NCI-SEER core as well as in strategic planning, policy development, staff hiring and performance evaluation, and other administrative duties.
- Prepare technical proposals, budgets, and budget justifications for various grant applications as well as prepare all contract deliverables, fiscal matters, and progress reports and final reports for special study projects that I serve as PI.
- Supervise the performance of several key LTR central staff including Education/Training Manager, Central Data Manager, Quality Assessment Coordinator, and Clinical Data Specialist.

Research Interests:

My research interests are in cancer epidemiology, cancer disparities, cancer outcomes, and cancer registration.

Teaching and Mentoring:

- Course director
 - EPPD 6226: Epidemiologic Design and Analysis (2023-present)
 - EPPH 7410: Teaching Practicum in Epidemiology (Fall 2025)
 - EPPH 7800: Prospectus Development (Fall 2025)
- Guest Lecturer:
 - EPID 6226: Epidemiologic Design and Analysis (2016-2022)
 - PUBH6120: Epidemiologic and Biostatistical Methods in Public Health (2024-2025)
- Epidemiology PhD qualifying exam
 - Design the questions.
 - Provide and update the answer key.
 - Grade the exam
 - Serve as a exam committee member (2025)
- **Serve as an academic advisor for PhD and MPH students.**
 - 7/2023-present
 - PhD: 1 (Co-Advisor)
 - MPH: 5
- **Mentoring**
 - Mentor graduate students (PhD, MS, and MPH) and/or LTR post-doctoral researcher to get hands-on experience in using cancer registry data.
 - Provide statistical support to graduate students on research projects.
 - Mentor student's practice experience: Epidemiology Program 1/19/2017 – 5/12/2017.
 - Serve on the faculty mentoring committee for School of Medicine: 6/2025-present
 - Mentee: Dr Richard Wells
 - Chair: Dr. David Welsh, Pulmonary/Critical Care, School of Medicine, LSU Health

Graduate Student Research Day:

- **Delta Omega Honors Day 2024:**
 - Sarah Northup, PhD student: 2nd place poster winner
 - Title: Analyzing Pre-Exposure Prophylaxis (PrEP) Persistence: Insights to Louisiana TelePrEP Program
 - Role: Statistical support
- **Graduate research day 2024:**
 - Shengdi Wen, PhD student
 - Title: Trend analysis on early-onset colorectal cancer incidence in Louisiana
 - Role: Mentor

Thesis and Dissertation Committees:

Served in Dissertation Committee:

- **Yichen Zhang**, PhD, Department of Health Policy and Management, School of Public Health and Tropical Medicine, Tulane University
Dissertation title: Treatment delay in Primary Non-Small Cell Lung Cancer (NSCLC) patients in Louisiana State, using REACHnet and Louisiana Tumor Registry (LTR) data

Timeframe: 8/2019-12/2021

Prospectus defense: January 21, 2020

Dissertation defense: November 1, 2021

- **Pratibha Shrestha**, PhD candidate, Epidemiology Program, School of Public Health, Louisiana State University Health Sciences Center-New Orleans.
Dissertation title: Breast Cancer Survival and treatment: Influences of Socioeconomic status, Oncotype DX use, Stage, Race, Rural-urban area, Age, distance to Radiation therapy facility
Timeframe: 7/2021-8/2023
Prospectus defense: November 29, 2021
Dissertation defense: May 30, 2023
- **Tingting Li**, PhD candidate, Epidemiology Program, School of Public Health, Louisiana State University Health Sciences Center-New Orleans.
Dissertation title: The Impact of Environmental Factors on Colorectal Cancer: Urban-Rural disparities, Incidence, Treatment, and Survival
Timeframe: 8/2021-8/2023
Prospectus defense: December 3, 2021
Dissertation defense: May 5, 2023
- **Tyler Prusisz**, PhD candidate, Epidemiology Program, School of Public Health, Louisiana State University Health Sciences Center-New Orleans.
Dissertation title: The Association of Oil Spill on Cancer Incidence, Mental Illness, and Lung Function
Timeframe: 11/2022 – 8/2024
Prospectus defense: January 20, 2023
Dissertation defense: June 6, 2024
- **Erica Washington**, PhD candidate, Epidemiology Program, School of Public Health, Louisiana State University Health Sciences Center-New Orleans.
Dissertation title: Impact of Colon Surgery on Infection Acquisition and Survival Among Colon Cancer Patients in Louisiana, 2015-2022
Timeframe: 2/2023 – present
Prospectus defense: May 13, 2024
Dissertation defense: TBD
Role: **Committee Administrator**
- **Sarah Northup**, PhD candidate, Epidemiology Program, School of Public Health, Louisiana State University Health Sciences Center-New Orleans
Dissertation title: Medicaid pharmacy claims to track the historical usage of PrEP in the state's Medicaid population
Timeframe: 9/2024 – present
Prospectus defense: December 6, 2024
Dissertation defense: TBD

Services:

- Serve as the graduate coordinator in Epidemiology and Population Health since 2022
- Served as a representative from the School of Public Health for the SACSCOC site visit – section 10.5 Admission Policies and Practices on March 25, 2025.

GRANTS AND CONTRACTS

Current

NIH/NCI/CDC

Role: Co-Principal Investigator (PI: Wu)

Title: Surveillance, Epidemiology and End Results Program (SEER Core)

Period: 5/1/2018-4/30/2028

Goal: The main goal of this program is to operate an efficient statewide cancer surveillance program, to provide cancer incidence and survival estimates, and to participate in collaborative cancer research.

Total Award: \$17.7 million (**Annual total award for 5/1/2018-4/30/2019:** \$1.8 million)

Percent of effort: 25% (3.0 calendar months)

NCI/SEER: HHSN261201800007I

Role: Co-Principal Investigator (PI: Wu)

Title: Cancer Prevention and Control Program for State, Territorial and tribal Organizations, National Program for Cancer Registries (NPCR Core).

NPCR Core Period: 6/30/2022-6/29/2027

Goal: The primary goals of this program are to enhance the Registry data and to maintain the standards of completeness, timeliness, and data quality.

Total Award: \$3,500,000

Percent of effort: 25% (3.0 calendar months)

CDC: NU58DP007112

Role: LSUHSC-NO site PI (Lead site PI: Laura Rozek, Georgetown University)

Title: Disparities and Cancer Epidemiology – Colorectal Cancer (DANCE-CRC)

(Project title: Aggressive colorectal cancer subtypes and social disadvantage in a racially diverse cohort.)

Goal: The major goal of this project is to assess aggressive colorectal cancer subtypes and social disadvantage in a racially diverse cohort

Period: 6/1/2021-5/31/2026

Budget requested: \$558,475 (Direct cost: \$379,915)

Percent of effort: 13% (1.56 calendar months) in year 1, 12% in year 2-3 (1.44 calendar months), and 3% (0.36 calendar months) in years 4-5

NIH/GU: R01CA259420/425573_AWD7775556-LSU

Role: LSUHSC site PI (PI: Jennifer Mack – Dana-Farber Cancer Institute/Harvard University)

Title: Disparities in Clinical Trial Enrollment among Adolescents and Young Adults (AYAs) with Cancer

Period: 9/19/2023-8/31/2028

0.72 calendar

Goal: To evaluate barriers of enrollment to clinical trials among AYAs with cancer aged 12-29 years and then use findings to develop an age-appropriate intervention to surmount identified barriers in a diverse population.

Budget requested: \$157,110 (Direct cost: \$104,740)

Percent of effort: 6%

NIH/DFCI: 1R01CA274484-01A1/ 1332201

Others:

Title: CIN3 data collection

Goal: The main goal is to continue collecting CIN3 cases and obtaining timely, complete, and high-quality CIN3 data to support the LSUHSC cancer center CIN3 cancer research.

Total Award: \$50,000

Percent of effort: 3.2% (0.38 calendar months)

LCMC

Pending

Role: Co-Investigator (PI: Chiranjeep Dash - GU)

Title: Addressing Social Determinants of Health-related Disparities in Early Onset Colorectal Cancer (1)

Period: 12/1/2025-11/30/2030

Percent of effort: 2%

American Cancer Society/ CHERC-RSG

Proposal ID: 1499783 (Submitted on 6/29/2025)

Role: Co-Investigator (PI: Laura Rozek - GU)

Title: Addressing Social Determinants of Health-related Disparities in Early Onset Colorectal Cancer (2)

Period: 12/1/2025-11/30/2030

Percent of effort: 2%

American Cancer Society/ CHERC-RSG

Proposal ID: 1521511 (Submitted on 6/29/2025)

Role: MPI (Contact PI: Jennifer Tsui - USC)

Title: Addressing Cervical Cancer Survivorship Quality of Care and Outcomes: The ACHIEVE Study II

Period: 4/1/2026-3/31/2031

Budget requested: \$447,470 (Direct cost: \$298,314)

Percent of effort: 10%

NIH/NCI: R01 PAR-25-301 (Submitted on 8/7/2025)

Role: MPI (Contact PI: Kendra Ratnapradipa - UNMC)

Title: Unraveling the epigenetic impact of unmet social needs in liver cancer

Period: 7/1/2026-6/30/2031

Goal: To evaluate the association of ADI and EAA with HCC diagnostic stage and 2-year survival by race as well as to evaluate the relationship of EAA as a mediator of ADI and HCC diagnostic stage and survival, and whether these relationships differ by race.

Budget requested: \$796,880 (Direct cost: \$539,415)

Percent of effort: 20%

NIH/NCI PA-25-301 (R01) (Submitted in 10/2025)

Completed

Role: LSUHSC site PI (Lead site PI: Maureen Sartor, University of Michigan)

Title: Downstream effects of HPV integration on survival/metastasis in oropharyngeal cancer.

Goal: To discover the predominant tumor subtypes and characteristics of AA oropharyngeal cancer, and to define the relationship between HPV integration and survival among AAs with oropharyngeal cancer.

Period: 7/1/2021-6/30/2022 (no cost extension to 6/30/2025)

Budget requested: \$55,406 (Direct cost: \$37,925)

Percent effort: 6.0% (0.72 calendar months)

NIH/UM: 1R01CA250214-01A1/ SUBK00013950

Role: LSUHSC-NO site PI (Lead site PI: Gita Suneja, University of Utah School of Medicine)

Title: Cancer Treatment Disparities in the HIV Population: Exploring the Impact of HIV on Physician and Patient Decision-Making

Goal: The major goal of this project is to understand oncologist treatment decision-making process for this specific patient population, as well as to develop decision support tools to improve delivery of cancer treatment for people living with HIV.

Period: 9/1/2021-8/31/2022 (no-cost extension to 8/31/2023)

Budget requested: \$30,963 (Direct cost: \$21,063)

Percent of effort: 6% (0.72 calendar months)

NIH/NCI/ University of Utah: 5K08CA228631-05/10054577-07-LSU

Role: LSUHSC-NO site PI (Lead site PI: Dr. Guergana Savova, Boston Children's Hospital/Harvard University)

Title: Natural Language Processing Platform for Cancer Surveillance

Goal: This study objectives are to develop methods to assist cancer data abstraction as well as to demonstrate the scalability of DeepPhe*CR through the integration in the SEER's Data Management System (SEER*DMS).

Period: 7/1/2022-6/30/2023

Budget requested: \$55,750 (Direct cost: \$37,925)

Percent effort: 6.0% (0.72 calendar months)

NIH/NCI/Boston Children's Hospital - Harvard University: UH3CA243120/ GENFD0002240331

Role: LSUHSC-NO site PI (Lead site PI: Dr. Yingnan Zhao- Xavier University /Dr. Lizheng Shi-Tulane University)

Title: Racial Disparity in Treatment and Monitoring among Louisiana Work-Age Survivors with Breast Cancer

Goal: This study aims to investigate treatment and monitoring patterns and assess racial disparities among work-age women with breast cancer in Louisiana (LA).

Period: 10/1/2021-6/30/2022 (no-cost extension to 6/30/2023)

Budget requested: \$2,777 (Direct cost only)

Percent effort: 1.5% (0.18 calendar months)

LCRC/Tulane: LCRC FY21-22/TUL-HSC-559900-21/22

Role: Co-Investigator (PI: Christopher Haiman, NCCC, University of Southern California; LSU Site PI: Wu)

Title: Research on Prostate Cancer in Men of African Ancestry: Defining the Roles of Genetics, Immunity and Access to Care – the RESPOND Study

Period: 7/5/2019-6/30/2023 (Study period: 7/5/2018-6/30/2023)

Goal: The objectives include investigation of multilevel social stressors across the life course in relationship with aggressive prostate cancer (Project 1); genome-wide discovery efforts of germline susceptibility loci for aggressive prostate cancer and examination of the relationship between germline and somatic variation (Project 2); the identification of underlying somatic alterations in prostate cancer tumors and biological pathways that are related to aggressive disease (Project 3); and, a detailed assessment of inflammation in the tumor microenvironment as it relates to prostate cancer aggressiveness (Project 4).

Total award: \$720,717

Percent of effort: 2% (0.24 calendar months)

NIH/USC: U19CA214253/122239979

Role: Co-Investigator 8/1/2020 - 7/31/2022 (PI: Ochoa)

Title: Gulf South Minority/Underserved Clinical Trials Network (Gulf South M/U CTN) (COVID supplement)

Period: 8/1/2020 - 7/31/2022

Goal: To collect COVID-19 related data items and assess the COVID-19 on the impact of cancer treatment

Total award: \$147,000

Percent of effort: 3% (0.36 calendar months) between 8/1/2020 - 7/31/2021

NIH/NCI: 3UG1CA189854-07S1

Role: Co-Principal Investigator (PI: Wu)

Title: Cancer Prevention and Control Program for State, Territorial and tribal Organizations, National Program for Cancer Registries (NPCR Core).

NPCR Core Period: 6/30/2017-6/29/2022

Goal: The main goals of this program are: to operate an efficient statewide cancer surveillance program, to provide cancer incidence and survival estimates, and to participate in collaborative cancer research.

Total Award: \$3,500,000 (Annual total award for 6/30/2017-6/29/2018: \$700,000)

Percent of effort: 25% (3.0 calendar months)

CDC: NU58DP006332

Role: Principal Investigator

Title: NPCR Component #2 - CIN III Project.

NPCR Component #2 Period: 6/30/2017-6/29/2022

Goal: The main goals of this program are: to build sustainable infrastructures for electronic collection of the CIN3 cases and required data items; to obtain timely, complete, and high-quality CIN3 data, and to participate in collaborative CIN3 cancer research.

Total Award: \$366,400

Percent of effort: 12% (1.44 calendar months)

CDC: NU58DP006332 (NPCR Component 2: CIN3)

Role: Principal Investigator

Title: Task order 1- CTRs to annotate and adjudicate clinical text documents within the SEER Program's Clinical Documentation Annotation and Processing (CDAP) Pipeline.

Task Order 2- Creation of a "gold standard" dataset of narrative clinical documents with annotated Personally Identifying Information (PII).

Period: 4/16/2020-8/15/2021

Goal: The main objective for this project is to develop NLP and machine learning tools and methods that automate data collection for cancer surveillance.

Total award: \$47,415.09

Percent of effort: 6% (0.72 calendar months)

NCI-SEER/Westat: Westat contract no: 6473-S10

Role: Co-Investigator (PI: Yu)

Title: Multilevel Mediation Analysis to Explore Racial Disparities in Breast Cancer Recurrence and Survival using CDC Special Studies

Period: 9/24/2017- 5/31/2020 (No cost extension to 5/31/2021)

Goal: The overall goal of this project is to identify and differentiate the effect of modifiable risk factors that contribute to the racial disparities in breast cancer recurrence and survival in United States in order to inform targeted precision medicine efforts.

Total award: \$438,000

Percent of effort: 5% (0.6 calendar months)

NIH (R15 PA-16-200): NIMHD 1R15MD012387

Role: Co-Investigator (PI: Wu)

Title: 10-Year Comparative Effectiveness and Harms of Treatment for Prostate Cancer (CEASAR)

Period: 4/1/2019-3/31/2021

Goal: Aim is to fill substantial knowledge gaps regarding intermediate- to long-term oncologic, quality of life, and financial toxicity outcomes of management for localized prostate cancer.

Total award: \$168,808 (Direct cost: \$115,926)

Percent of effort: 2% (0.24 calendar months)

Vanderbilt MC/NIH: VUMC73449 (1R01CA230352)**Role:** LSUHSC-NO Site Principal Investigator (PI: Dr. Lizheng Shi – Tulane University)**Title:** Clinical Pathway among Patients with Lung Cancer: REACHnet and Louisiana Tumor Registry (LTR)**Period:** 2/1/2019-4/15/2020 (No cost extension to 10/15/2020)**Goal:** As a supplemental study for the existing Truven study, this proposal aims to describe the clinical pathway from undertaking the first biopsy for lung cancer diagnosis to the treatment after diagnosis overall and stratified according to lung cancer (LC) subtypes.**Total award:** \$89,926**Percent of effort:** 10% (1.2 calendar months)**Funding: Intuitive Surgical Operation, Inc. (Contract through Tulane):** TUL-HSC-557012-18/19**Role:** Co-Investigator (PI: Leonardi)**Title:** Feasibility of Electronic Health Records to Study Social Determinants of Health Disparities in Hepatocellular Carcinoma in Louisiana**Period:** 7/1/2018-12/31/2019**Goal:** The goal of this project are to assess the representativeness of HCC cases in REACHnet compared to the population of known cases in the state registry and to determine the feasibility of a case-control study to investigate clinical risk factors of HCC (i.e., BMI, diabetes, Hepatitis C status, substance use disorder) from EHRs.**Total award:** \$50,000**Percent of effort:** 1% (0.12 calendar months)**U54 GM104940 /LA CaTS Round 7****Role:** Principal Investigator (9/30/2016-9/29/2019)

Co- Principal Investigator (9/30/2015-9/29/2016) (PI: Wu)

Data Manager (9/30/2014-9/29/2015) (PI: Chen)

Title: Enhancing Cancer Registries for early Case Capture (ECC) of Pediatric and Young Adult Cancer**Period:** 9/30/14-9/29/19**Goal:** The objectives of this ECC project are to enhance its routine cancer surveillance activities and build sustainable infrastructure for identifying newly-diagnosed pediatric and young adult (ages 0-19) cancer cases within 30 days of diagnosis. The ultimate goal is to increase the availability of timely pediatric cancer data for the surveillance, clinical, and research communities.**Total award:** \$1,270,325 (**Annual Total award** 9/30/2014-9/29/2015: \$263,235; 9/30/2015-9/29/2016: \$270,310; 9/30/2016-9/29/2017: \$210,310; 9/30/2017-9/29/2018: \$270,130)**Percent of effort:** 10% (1.2 calendar months)**CDC:** NU58DP005390**Role:** Principal Investigator**Title:** Cases Investigation of Cervical Cancer (CICC) Study

Periods: 2/21/2016-10/31/2018

Goal: The purpose of CICC project is to conduct a case investigation of invasive cervical cancers to identify potential missed opportunities for proven public health interventions, identify programmatic weaknesses, and determine the barriers and facilitators to screening.

Total award: \$227,140

Percent of effort: 8%

CDC/Battelle: HHSD2002013M53942B/ SUBCONTRACT NO: PO #: US001-0000524274

Role: Co-Principal Investigator (5/1/2017-4/30/2018)

Data Manager (8/1/2012-4/30/2017)

Title: Surveillance, Epidemiology and End Results Program (SEER Core)

Period: 8/1/12 to 4/30/18

Goal: The main goal of this program is to operate an efficient statewide cancer surveillance program, to provide cancer incidence and survival estimates, and to participate in collaborative cancer research.

Total Award: \$9,781,887(**Annual total award for 8/1/2012-7/31/2013:** \$1,641,007; 8/1/2013-7/31/2014: \$1,378,312; 6/1/2014-4/30/2015: \$1,554,054; 5/1/2015-4/30/2016: \$1,707,739; **5/1/2016-4/30/2017: \$1,734,523; 5/1/2017-4/30/2018: \$1,766,252**)

Percent of effort: 30.0%

NCI/SEER: HHSN261201300016I (HHSN26100006, Modification 2) (PI: Wu)

Role: Principal Investigator

Title: Height and weight data to calculate a valid measure of mass index.

Periods: 9/19/2016-9/18/2017

Goal: The main goals are to obtain data on cancer patient's height and weight from the department of Motor Vehicles (DMV) through linkage and to compare BMI for individuals computed using medical record abstraction to the same measure computed using DMV records.

Total Award: \$47,456

Percent of effort: 8%

NCI/SEER: HHSN261201300016I/HHSN26100011

Role: Principal Investigator

Title: Improving outpatient reporting of cancer occurrence and treatment.

Periods: 9/19/2016-9/18/2017

Goal: The main goal is to evaluate the under reporting of incident cancer cases seen at free standing medical oncology outpatient clinics with a focus on hematopoietic diseases.

Total Award: \$80,890

Percent of effort: 8%

NCI/SEER: HHSN261201300016I/HHSN26100012

Role: Co-Principal Investigator

Title: Population-based evaluation of comorbidity and hospital characteristics on survival.

Periods: 9/19/2016-9/18/2017

Goal: The main goal is to link rare cancer cases from the Louisiana Tumor registry with records from Louisiana Hospital Inpatient Discharge data (HIDD) to obtain patient comorbidity information and hospital treatment information.

Total Award: \$59,900

Percent of effort: 5%

NCI/SEER: HHSN2612013000161/HHSN26100013 (PI: Wu)

Role: Co-Principal Investigator

Title: Cancer Prevention and Control Program for State, Territorial and tribal Organizations, Component #4, National Program for Cancer Registries (NPCR) and Patient Centered Outcomes Research (PCOR).

NPCR Core Period: 6/30/2012-6/29/2017

PCOR Period: 8/29/2015-6/29/2017

Goal: The main goals of this program are: to operate an efficient statewide cancer surveillance program, to provide cancer incidence and survival estimates, to participate in collaborative cancer research, and to continue data collection of disease recurrence, progression, and vital status for CER cases, defined here as 2011 breast, colon, and rectal cancer cases.

Total Award: \$3,858,414

Percent of effort: 20%

CDC: NU58DP003915 (PI: Wu)

Role: Principal Investigator

Title: Improve Completeness of treatment and Other Key Data Elements by Linkages with 15-month Resubmitted Data from Commission on Cancer Hospitals.

Periods: 9/18/2015-9/17/2016

Goal: The main goal is to explore an innovative method to obtain complete treatment data as well as other key data items from COC hospitals using 15-month data resubmission and linkages.

Total Award: \$55,275

Percent of effort: 5%

NCI: HHSN2612013000161/HHSN26100009

Role: Co-Principal Investigator

Title: Expanding Data Collection Infrastructure of National Program of Cancer Registries (NPCR) for Patient Centered Outcomes Research (PCOR)

Period: 3/1/2014-8/28/2015

Goal: The main goal is to enhance Specialized Cancer Registries by creating datasets for CER with extended longitudinal follow-up and data collection of disease recurrence, progression, and vital status for CER cases, defined here as 2011 breast, colon, and rectal cancer cases.

Total Award: \$413,218

CDC/IFC-Macro: Subcontract #: 1eEDSK0106 (PI: Chen/Wu)

Role: Data Manager

Title: Enhancing Cancer Registries for early Case Capture (ECC) of Pediatric and Young Adult

Period: 9/30/2011-9/29/2014

Goal: The objectives of this ECC project are to enhance its routine cancer surveillance activities and build sustainable infrastructure for identifying newly-diagnosed pediatric and young adult (ages 0-19) cancer cases within 30 days of diagnosis. The ultimate goal is to increase the availability of timely pediatric cancer data for the surveillance, clinical, and research communities.

Total award: \$794,092

CDC: 1U58DP003805 (PI: Chen)

Role: Data Manager

Title: Enhancing Cancer Registry Data Comparative Effectiveness Research (CER)

Period: 12/1/2010-9/30/2013

Goal: Become a Specialize Cancer Registry of NPCR, utilizing a two-pronged approach to enhance the Louisiana registry data for CER by: (1) conducting a pattern of care study of cancers of breast, colon and rectum and chronic myeloid leukemia (CML) diagnosed in 2011 and (2) improving electronic reporting from non-hospital settings and additional linkages of secondary data files to capture data items that are relevant to CER.

Total Award: \$1,558,053

CDC/ICF: #635243-10S-1566 (PI: Chen)

Not Funded

Role: MPI (Contact PI: Kendra Ratnapradipa - UNMC)

Title: Evaluating Racial Disparities in DNA Methylation as a Mediator of Area Deprivation and Liver cancer Prognosis and Outcomes

Period: 12/1/2025-11/30/2030

Goal: To evaluate the association of ADI and EAA with HCC diagnostic stage and 2-year survival by race as well as to evaluate the relationship of EAA as a mediator of ADI and HCC diagnostic stage and survival, and whether these relationships differ by race.

Budget requested: \$796,880 (Direct cost: \$539,415)

Percent of effort: 20%

NIH/NCI PA-25-121 (R01) (Submitted on 1/31/2025)

Role: LSU site PI (PI: Kristen Purrington – Wayne State University)

Title: Racial Differences in Tumor Biology and Implications for Novel Approaches to Treatment among Women with ER+, HER2- Breast Cancer

Period: 12/1/2022-11/30/2027

1.2 calendar

Goal: To experimentally identify racial differences in estrogen signaling and anti-estrogen response among ER+ and ER- tumor cell subpopulations in weakly ER+ tumors using a novel short-term patient tumor engraftment model and single cell RNA-seq

Budget requested: \$333,580 (Direct cost: \$226,925)

Percent of effort: 10%

NIH/NCI PAR-21-322[R01]

Role: Co-Investigator and LSU site PI (Lead Site PI: Tony Hu – Tulane University)
Title: Extracellular Vesicle Biomarkers Assay for Pancreatic Cancer Disparity Study
Period: 8/1/2023-7/31/2025 0.6 calendar
Goal: To systemically analyze intrinsic inherited EV biomarkers with known PC associations, and identify potential causal molecular biomarkers for pancreas cancer prevalence in racial disparities.
Budget requested: \$51,601 (Direct cost: \$34,401)
Percent of effort: 6% Year 1 and 5% Year 2
NIH/NCI: PAR-22-114

Role: LSUHSC-NO Site PI (Lead site PI: Brock O’Neil –University of Utah/Health Cancer Institute)
Title: Cost, Quality, and Unintended Consequences of the Radiation Oncology Model
Period: 4/1/2022-3/31/2027
Goal: To determine whether the Radiation Oncology Model (ROM) improves the value of radiotherapy for cancer while investigating possible unanticipated consequences.
Budget requested: \$223,399 (Direct cost: \$151,973)
Percent of effort: 10% (1.2 calendar months) in Year 1, 6% (0.72 calendar months) in year 2 and 5% (0.6 calendar months) in years 3-5
NIH/NCI

Role: LSUHSC-NO Site PI (Lead site PI: Ronald Chen –University of Kansas Cancer Center)
Title: A Population-Based Prostate Cancer Active Surveillance (AS) Cohort
Period: 6/1/2021-5/31/2027
Goal: To reduce mortality and maximize the QOL for patients with localized prostate cancer
Budget requested: \$335,953 (Direct cost: \$228,539)
Percent of effort: 15% (1.8 calendar months) in Year 1, 10% (1.2 calendar months) in year 2 and 5% (0.6 calendar months) in years 3-6
NIH/NCI RFA-CA-20-030: “Utilizing Cohort Studies to Address Health Outcomes in Cancer Survivors”

Role: LSUHSC-NO Site PI (Lead site PI: Dr. Pierce, University of South Alabama Mitchell Cancer Institute)
Title: Machine Learning Techniques in Multilevel Mediation Analysis to Explore Health Disparities
Period: 7/1/2020-6/30/2025
Total funds requested: \$14,492
Percent of effort: 127 total hours
NIH/NCI

Role: Co-Investigator (PI: Yu)
Title: Machine Learning Techniques in Multilevel Mediation Analysis to Explore Health Disparities
Period: 01/01/2021-12/31/2025

Total funds requested: \$605,287

Percent of effort: 5% (0.6 calendar months)

National Science Foundation: NSF 19-575 Methodology, Measurement & Statistics Program

Role: LSUHSC-NO Site PI (Lead site PI: Alan Geller – Harvard University)

Title: Reducing Risk of Advanced Skin Cancers among Adult Survivors of Childhood Cancer via State and SEER Cancer Registries.

Period: 9/1/2020-8/31/2025

Goal: To study the dissemination of print materials and text messages to adult survivors of childhood cancer who were treated with radiation about their increased risk of developing skin cancer and the need for regular skin cancer screenings.

Total funds requested: \$255, 403 (Direct cost: \$173,744)

Percent of effort: 5% (0.6 calendar months)

NIH/NCI U01 RFA-CA-19-033: “Improving Outcomes for Pediatric, Adolescent and Young Adult Cancer Survivors” (Re-submitted December 2019)

Role: Co-Investigator (PI: Yu)

Title: Modern Modeling in Multilevel Mediation Analysis to Explore Cancer Disparities

Period: 1/1/2021 to 12/31/2025

Total funds requested: \$2,270,058

Percent of effort: 5% (0.6 calendar months)

NIH/NCI: R01 RFA PA-17-289 Leveraging Population-based Cancer Registry Data to Study Health Disparities.

Role: LSU site PI (PI: Jennifer Pierce, MD. Mitchell Cancer Institute, University of South Alabama)

Title: Beyond Access: Cervical Cancer after Medicaid Expansion in the Deep South

Period: 7/1/2020-6/30/2025

Percent of effort: Total of 127 hours

ACS: # RSGI CPHPS - 134641

Role: Co-Investigator (PI: Yu)

Title: Exploring Racial/Ethnic Disparities in Health-Related Quality of Life among Cancer Survivors Considering both Individual and Environmental Level Risk Factors

Period: 10/1/2019-9/30/2021

Total funds requested: TBD

Percent of effort: 5% (0.6 calendar months)

NIH/NCI: R21CA231479

Role: Principal Investigator

Title: Developing Information Collection Tools for a Feasibility Study of a Mesothelioma Patient Registry

Period: 8/1/2019-7/31/2021

Goal: The goal of this project is to rapidly identifying mesothelioma patients and conduct survey to collect risk factors that patients exposed and perform medical chart abstraction to collect cancer related information.

Total funds requested: \$85,018

Percent of effort: 5% (0.6 calendar months)

CDC: RFP#: 75D301-19Q-70489

Role: Co-Investigator (PI: Leonardi)

Title: Social Determinants of Disparities in Hepatocellular Carcinoma

Period: 4/1/2019-3/31/2024

Goal: The goal of this project is to assess the degree to which social determinants of health behavior and chronic stress are associated with hepatocellular carcinoma incidence and related disparities within Louisiana.

Percent of effort: 5% (0.6 calendar months)

NIH/NCI: R21

Role: Co-I (LSUHSC PI: Hui-Yi Lin)

Title: Oxidative Stress and Related Genetic Modification Associated with Prostate Cancer Aggressiveness and Survival.

Period:

Goal: The objective of this study is to evaluate 4 OS biomarkers, PRS, and the related OS-gene interactions associated with PCa aggressiveness and PCa-specific survival. The OS-SNP interactions will be evaluated using a novel statistical method developed by our team.

Budget requested:

Percent of effort: 2%

NIH/NCI:

PUBLICATIONS

Peer-Reviewed:

1. Chen VW, Schmidt BA, Wu XC, Correa CN, Andrews PA, **Hsieh MC**, Ahmed MN. Childhood Cancer in Louisiana, 1988-1996. *J LA Med Soc.* 2002; 154(2): 91-99. PMID: 12014461.
2. Wu XC, Chen VW, Ruiz B, Andrews PA, **Hsieh MC**, Schmidt BA, Correa CN, Fonham ETH. Patterns of Treatment for Ductal Carcinoma In Situ of the Breast in Louisiana, 1988-1999. *J LA Med Soc.* 2003; 155(2):206-213. PMID: 14506828.
3. Wu XC, Chen VW, Andrews PA, Chen L, **Hsieh MC**, Fonham ETH. Treatment Patterns for Stage III Colon Cancer and Factors Related to Receipt of Postoperative Chemotherapy in Louisiana. *J LA Med Soc.* 2004;156(5):255-261. PMID: 15554095.
4. Wu XC, Chen VW, Andrews PA, Chen L, Ahmend MN, Schmidit BA, **Hsieh MC**, Fonham ETH. Initial Treatment Patterns for Clinically Localized prostate Cancer and Factors Associated with the Treatment in Louisiana. *J LA Med Soc.* 2005;157(4):188-194. PMID: 16250368.

5. Boscoe FP, Schymura MJ, **Hsieh MC**, Williams, MA, Henry KA. Issues with the Coding of Pacific Islander in Central Cancer Registries. *J Registry Manag.* 2008;35(2):47-51.
6. Schymura MJ, Khan AR, German RR, **Hsieh MC**, Cress RD, Finch JL, Fulton JP, Shen T, Stuckart E. (2010) Factors associated with initial treatment and survival for clinically localized prostate cancer: results from the CDC-NPCR Patterns of Care Study (PoC1). *BMC Cancer.* **10**(1): p. 152. PMID: 20403178. PMCID: PMC2876077. DOI:10.1186/1471-2407-10-152.
7. **Hsieh MC**, Pareti LA, Chen VW. Using NAPIIA to Improve the Accuracy of Asian Race Codes in Registry Data. *J Registry Manag.* 2011; **38**(4): 190-195. PMID: 23270092.
8. **Hsieh MC**, Velasco C, Wu XC, Pareti LA, Andrews PA, Chen VW. Influence of Socioeconomic Status and Hospital Type on Disparities of Lymph Node Evaluation in Colon Cancer Patients. *Cancer.* 2012;118(6): 1675-1683. DOI: 10.1002/cncr.26473. PMID: 21882179, PMCID: PMC3767484
9. **Hsieh MC**, Yu Q, Wu XC, Wohler B, Fan Y, Qiao B, Jemal A, Ajani UA. Evaluating Factors Associated with Unknown SEER Summary Stage 2000 Derived from Collaborative Stage at Central Registry Level. *J Registry Manag.* 2012; **39**(3): 101-106. PMID: 23443453. **Awarded as the Best Paper of Year 2012.**
10. **Hsieh MC**, Wu XC, Andrews PA, Chen VW. Racial and Ethnic Disparities in the Incidence and Trends of Soft Tissue Sarcoma among Adolescents and Young Adults in the United States, 1995-2008. PMID: 24066270, PMCID: PMC3778995. *JAYAO.* 2013; **2**(3): 89-94. DOI:10.1089/jayao.2012.0031.
11. **Hsieh MC**, Chiu YW, Velasco C, Wu XC, O'Flarity MB, Chen VW. Impact of Race/Ethnicity and Socioeconomic Status on Adjuvant Chemotherapy Use among Elderly Patients with Stage III Colon Cancer. *J Registry Manag.* 2013; **40**(4): 180-187. PMID: 24625772.
12. Fan Y, Yu Q, Wu X, **Hsieh MC**. Data Quality Evaluation Using MART Guided Generalized Linear Mixed Model - With Application to Evaluate the SEER Cancer Staging Data. *Journal of Data Analysis & Operations Research.* 2014; **1**(1): 17-24.
13. Chen V W, Ruiz BA, **Hsieh MC**, Wu XC, Ries LA, Lewis DR. Analysis of Stage and Clinical/Prognostic Factors for Lung Cancer from SEER Registries: AJCC Staging and Collaborative Stage Data Collection System. *Cancer.* 2014; **120**(Issue Supplement S23): 3781-3792. PMID: 25412390, PMCID: PMC4239667. DOI: 10.1002/cncr.29045.
14. Chen VW, **Hsieh MC**, Charlton ME, Ruiz BA, Karlitz J, Altekruise S, Ries LA, Jessup JM. Analysis of Stage and Clinical/Prognostic Factors for Colon and Rectal Cancer from SEER Registries: AJCC and Collaborative Stage Data Collection System. *Cancer.* 2014; **120**(Issue Supplement S23):3793-3806. PMID: 25412391, PMCID: PMC4239669. DOI: 10.1002/cncr.29056.
15. Altekruise S, Dickie L, Wu XC, **Hsieh MC**, Wu M, Lee R, Delacroix Jr. S. Clinical and Prognostic Factors for Renal Parenchymal, Pelvis, and Ureter Cancers in SEER Registries: Collaborative Stage Data Collection System, Version 2. *Cancer.* 2014; **120**(Issue Supplement S23): 3826-3835. PMID: 25412394. DOI: 10.1002/cncr.29051.
16. Chen VW, Ehemann CR, Johnson CJ, Hernandez MN, Rousseau D, Styles TS, West DW, **Hsieh MC**, Hakenewerth AM, Celaya MO, Rycroft RK, Wike JM, Pearson M, Brockhouse J, Mulvihill LG, Zhang KB. Enhancing Cancer Registry Data for Comparative Effectiveness

- Research (CER) Project: Overview and Methodology. *J Registry Manag.* 2014; 41(3):103-112. PMID: 25419602.
17. Karlitz JJ, **Hsieh MC**, Liu Y, Blanton C, Schmidt B, Jessup JM, Wu XC, Chen VW. Population-based Lynch Syndrome Screening by Microsatellite Instability in Patients \leq 50: Prevalence, Testing Determinants and Result Availability Prior to Colon Surgery. *Am J Gastroenterol.* 2015 Jul;110(7):948-55. PMID: 25601013. DOI: 10.1038/ajg.2014.417.
 18. Li X-R, Kruchko C, Wu X-C, **Hsieh M-C**; Andrews PA, Huang B, Qiao B, Wohler B. Are benign and borderline brain tumors underreported? *J Registry Manag.* 2016; 43 (4):187-194. PMID: 29595921.
 19. Karlitz JJ, Sherrill MR, DiGiacomo DV, **Hsieh M-C**, Schmidt B, Wu X-C, Chen VW. Factors associated with the performance of extended colonic resection vs. segmental resection in early-onset colorectal cancer: a population-based study. *Clin Transl Gastroenterol.* 2016 Apr 14;7: e163. PMID: 27077958, PMCID: PMC4855160. DOI:10.1038/ctg.2016.17.
 20. **Hsieh MC**, Thompson T, Wu XC, Styles TS, O'Flarity MB, Morris C, Chen VW. The effect of comorbidity on the use of adjuvant chemotherapy and type of regimen for curatively resected stage III colon cancer patients. *Cancer Medicine.* 2016; 5(5): 871-880. PMID: 26773804. PMCID: PMC4864816. DOI: 10.1002/cam4.632.
 21. Rico A, Pollack LA, Thompson TD, **Hsieh M-C**, Wu X-C, Karlitz JJ, West DW, Rainey JM, Chen VW. KRAS testing and first-line treatment among patients diagnosed with metastatic colorectal cancer using population data from ten National Program of Cancer Registries in the United States. *J Cancer Res Ther.* 2016, 5(2):7-13. PMID: 28626587; PMCID: PMC5472357. DOI: 10.14312/2052-4994.2017-2.
 22. **Hsieh M-C**, Mumphrey B, Pareti LA, Yi Y, Wu X-C. Innovative approach to improve completeness of treatment and other key data elements in population-based cancer registry: A 15-month data submission. *J Registry Manag.* 2017; 44(2):69-75. PMID: 29611688. **Awarded as the Best Paper of Year 2017 Honorable Mention.**
 23. Freeman MB, Pollack LA, Rees JR, Johnson CJ, Rousseau DL, **Hsieh M-C**. Capture and Coding of Industry and Occupation Measures: Findings from 8 National Program of Cancer Registries States. *Am J Ind Med.* 2017; 60:689-695. PMID: 28692191. PMCID: PMC5769461.
 24. Wu EL, Riley CA, **Hsieh M-C**, Marino MJ, Wu X-C, McCoul ED. Chronic sinonasal tract inflammation as a precursor to nasopharyngeal carcinoma and sinonasal malignancy in the United States. *Int Forum Allergy Rhinol.* 2017;7(8): 786-793. PMID: 28549211. DOI: 10.1002/alr.21956
 25. Riley CA, Wu EL, **Hsieh M-C**, Marino MJ, Wu X-C, McCoul ED. Association of gastroesophageal reflux with malignancy of the upper aerodigestive tract in elderly patients. *JAMA Otolaryngol Head Neck Surg.* February 2018;144(2):140-148. PMID: 29270624. PMCID: PMC5839296. DOI: 10.1001/jamaoto.2017.2561.
 26. Zhang L, Yu Q, Wu X-C, **Hsieh M-C**, Loch M, Chen V, Fontham E, Ferguson T. Impact of chemotherapy relative dose intensity on cause-specific and overall survival for stage I-III breast cancer: ER+/PR+, HER2- vs. Triple-Negative. *Breast Cancer Res Treat.* 2018 May; 169(1):175-187. PMID: 29368311. PMCID: PMC6190707. DOI: 10.1007/s10549-017-4646-1.

27. **Hsieh M-C**, Van Dyne E, Lefante C, Shapiro JA, Lynch MA, Pordell P, Gomez N, Mumphrey B, Maniscalco L, Jetly-Shridhar R, Saraiya M; Wu X-C. Evaluating the Use of LAST Two-tiered Nomenclature and Its Impact on Reporting Cervical Lesions in a Population-Based Cancer Registry. *J Registry Manag.* 2019; 46(4):120-127. PMID: 32822336. **Awarded as the Best Paper of Year 2019.**
28. Zhang L, King J, Wu X-C, **Hsieh M-C**, Chen VW, Yu Q, Fontham E, Loch M, Pollack LA, Ferguson T. Racial/ethnic Differences in the utilization of chemotherapy among stage I-III breast cancer patients, stratified by subtype: Findings from ten National Program of Cancer Registries States. *Cancer Epidemiology* 2019;58:1-7. PMID: 30415099. PMCID: PMC6424114. DOI: 10.1016/j.canep.2018.10.015.
29. Riley CA, Marino MJ, **Hsieh M-C**, Wu EL, Wu X-C, McCoul ED. Detection of laryngeal carcinoma in the U.S. elderly population with gastroesophageal reflux disease. *Head & Neck* 2019; 41:1434-1440. PMID: 30681216. DOI: 10.1002/hed.25600.
30. **Hsieh M-C**, Zhang L, Wu X-C, Davison MB, Loch M, Chen VW. Population-based study on cancer subtypes, guideline-concordant adjuvant therapy, and survival among women with stage I-III breast cancer. *J Natl Compr Canc Netw* 2019;17(6):676-686. PMID: 31200362. DOI: <https://doi.org/10.6004/jnccn.2018.7272>.
31. Marino MJ, **Hsieh M-C**, Wu EL, Riley CA, Wu X-C, McCoul ED. Early versus late computed tomography and nasal endoscopy in the diagnosis of nasopharyngeal and paranasal sinus malignancy. *American Journal of Rhinology & Allergy.* 2019; 33(4): 388-394. PMID: 30900468. DOI: [10.1177/1945892419838106](https://doi.org/10.1177/1945892419838106)
32. Benard V, Greek A, Jackson E, Senkomago V, **Hsieh M-C**, Crosbie A, Alverson G, Troup A, Richardson L, Tomas CC. Overview of CDC's Case Investigation of Cervical Cancer (CICC) Study. *Journal of Women's Health.* 2019;28 (7): 890-896. PMID: 31264934. Published Online: July 2, 2019. <https://doi.org/10.1089/jwh.2019.7849>.
33. Thompson TD, Pollack LA, Johnson CJ, Wu X-C, Rees JR, **Hsieh M-C**, Rycroft R, Culp MB, Wilson R, Wu M, Zhang K, Benard V. Breast and Colorectal Cancer Recurrence and Progression Captured by Five U.S. Population-Based Registries: Findings from National Program of Cancer Registries Patient-Centered Outcome Research. *Cancer Epidemiology.* 2020; 64: 1-9. PMID: 31918179. Published Online: January 6, 2020. <https://doi.org/10.1016/j.canep.2019.101653>.
34. Zhang L, **Hsieh M-C**, Petkov V, Yu Q, Chiu Y-W, Wu X. Trend and survival benefit of Oncotype DX use among female hormone receptor positive breast cancer patients in 17 SEER registries, 2004-2015. *Breast Cancer Res Treat.* 2020; 180(2):491-501. PMID: 32060781. DOI: 10.1007/s10549-020-05557-x.
35. Chu QD, **Hsieh M-C**, Chu YD, Lyons J, Kandil E, Corsetti R, Gnerlich J, Wu X-C. Do Rural Patients with Operable Breast Cancer Fare Worse Than Urban Patients in Louisiana? Results of the Louisiana Cancer Consortium. *Surgery.* 2020;168: 653-661. PMID: 32622472. <https://doi.org/10.1016/j.surg.2020.04.053>.
36. Fischer JL, Riley CA, **Hsieh M-C**, Marino MJ, Wu X-C, McCoul ED. Prevalence of Eustachian Tube Dysfunction in the United States Elderly Population. *Otolaryngology-Head and Neck Surgery.* 2020; 163(6) 1169-1177. PMID: 32573346. <https://doi.org/10.1177/0194599820932541>.

37. Qiao B, **Hsieh M-C**, Wu X-C, Kruchko C, Sineshaw H, Wu M, Huang B, Sherman R, Ostrom QT, Yu Q, Schymura MJ. Multiple primary cancers in the United States. *J Registry Manag.* 2020;47(2):60-66. PMID: 35363672.
38. Chu QD, Li T, **Hsieh M-C**, Yi Y, Gibbs JF, Chu YD, Lyons J, Wu X-C. Positive Impact of Affordable Care Act (ACA) Medicaid Expansion on Louisiana Women with Breast Cancer. *Cancer.* 2021;127(5):688-699. PMID: 33142360. DOI: 10.1002/cncr.33265.
39. Chu QD, Gibbs JF, Lyons JM, Li T, **Hsieh M-C**, Yi Y, Wu X-C. Data Demonstrating a Lack of Black/White Parity in Breast Cancer Mortality Following Medicaid Expansion. Are the Data Granular Enough to Support This? *JCO Glob Oncol.* 2021 Feb;7:183-184. PMID: 33529078. DOI: 10.1200/GO.20.00428.
40. Zhang Y, Simoff MJ, Ost O, Wagner O, Lavin J, Nauman B, **Hsieh M-C**, Wu X-C, Pettiford B, Shi L. Understanding the Patient Journey to Diagnosis of Lung Cancer. *BMC Cancer.* 2021 Apr 14;21(1):402. PMID: 33853552 PMCID: PMC8045203 DOI: 10.1186/s12885-021-08067-1.
41. Chu QD, **Hsieh M-C**, Lyons JM, Wu X-C. 10 year survival after breast-conserving surgery is better than mastectomy for Louisiana women with early-stage breast cancer: A population-based study. *J Am Coll Surg.* 2021; 232(4): 607-621. PMID: 33301909. DOI: 10.1016/j.jamcollsurg.2020.11.011
42. Lyons JM, Chu QD, **Hsieh M-C**, Wu X-C. Breast-Conserving Therapy vs Mastectomy for Early-Stage Breast Cancer: Should We Re-Evaluate the Current Treatment Paradigm? *J Am Col Surg.* 2021 May; 232(5): 801-802. S1072-7515(21)00013-2. PMID: 33551182. DOI: 10.1016/j.jamcollsurg.2021.01.003.
43. Neroda P, **Hsieh M-C**, Wu X-C, Cartmell K, Mayo R, Wu J, Hicks C, Zhang L. Racial disparity and social determinants in receiving timely surgery among stage I-IIIa non-small cell lung cancer patients in a U.S. southern state. *Front Public Health.* 2021; 9: 662876. PMID: 34150706, PMCID: PMC8206495. DOI: 10.3389/fpubh.2021.June.662876
44. Zhang L, **Hsieh M-C**, Kelly C, Devane M, Yu Q, Shi L, Wu J, Hicks C, Wu X-C. Racial Differences in the Risk of Second Primary Bladder Cancer Following Radiation Therapy among Prostate Cancer Patients. *Cancer Epidemiology.* 2021 Jun 17;73: 101967. PMID: 34146916. <https://doi.org/10.1016/j.canep.2021.101967>
45. Zhang L, **Hsieh M-C**, Rennert L, Neroda P, Wu X-C, Hicks C, Wu J, Gimbel R. Diagnosis-to-surgery interval and survival for different histologies of stage I-IIA lung cancer. *Transl Lung Cancer Res* 2021 Jul;10(7):3043-3058. PMID: 34430346. PMCID: PMC8350104. doi: 10.21037/tlcr-21-168.
46. Li B, Yu Q, Zhang L, **Hsieh M**. Regularized Multiple Mediation Analysis. *Statistics and Its Interface (SII).* 2021 Jul; 14(4):449-458. DOI: <https://dx.doi.org/10.4310/21-SII664>.
47. Zhou M, Thompson T, Li H-Y, Chen VW, Karlitz J, Fontham ETH, Theall KP, Zhang L, **Hsieh M-C**, Pollack LA, Wu X-C. Impact of relative dose intensity of FOLFOX adjuvant chemotherapy on risk of death among stage III colon cancer patients. *Clinical Colorectal Cancer.* 2021. Published online October 01, 2021. PMID: 34756680. DOI:<https://doi.org/10.1016/j.clcc.2021.09.008>
48. Chu QD, **Hsieh M-C**, Gibbs JF, Wu X-C. Social determinants of health associated with poor outcome for rural patients following resected pancreatic cancer. *J Gastrointest*

Oncol 2021 Dec;12(6):2567-2578. PMID: 35070388 PMCID: PMC8748046. doi: 10.21037/jgo-20-583.

49. Chu QD, **Hsieh M-C**, Gibbs JF, Wu X-C. Treatment at a high-volume academic research program mitigates racial disparities in pancreatic adenocarcinoma. *J Gastrointest Oncol* 2021 Dec;12(6):2579-2590. PMID: 35070389 PMCID: PMC8748054 DOI: 10.21037/jgo-20-584.
50. **Hsieh M-C**, Zhang L, Velasco-Gonzalez C, Yi Y, Pareti LA, Trapido EJ, Chen VW, Wu-X-C. Impact of Diabetes and Modifiable Risk Factors on Pancreatic Cancer Survival in a Population-based Study after Adjusting for Clinical Factors. *Cancer Causes & Control*. 2022 Jan;33(1):37-48. PMID: 34633573. doi: 10.1007/s10552-021-01497-z (Publicly share link at <https://rdcu.be/czlqk>)
51. Warren J, Noone A-M, Stevens J, Wu X-C; **Hsieh, M-C**; Mumphrey B, Schmidt R, Coyle L, Shields R, Mariotto A. The Utility of Pathology Reports to Identify Persons with Cancer Recurrence. *Medical Care*. 2022 Jan; 60(1): 44-49. PMID: 34812787; PMCID: PMC8720471. DOI: 10.1097/MLR.0000000000001669
52. Chu QD, **Hsieh M-C**, R Candal, Yi Y, Lyons J, Wu X-C. Outcomes of Breast-conserving surgery plus radiation yielded better outcomes than mastectomy for all subtypes of early-stage breast cancer: Analysis of over 200,000 women. *J Am Coll Surg*. 2022 Apr 1;234(4):450-464. PMID: 35290264. DOI: 10.1097/XCS.000000000000100
53. Yu Q, Zhu L, Zhang L, **Hsieh M**, Wu, X. Li B. Multiple Third-Variable Analysis for Competing-Risk Data -- With an Application to Explore Racial Disparity in Breast Cancer Recurrence. *Stat*. 2022 July 14; 12:e488. PMID: 39896263. PMCID: PMC11784982. <https://doi.org/10.1002/sta4.488>
54. Shrestha P, Chu Q, **Hsieh M-C**, Yi Y, Peters E, Trapido E, Yu Q, Ferguson T, Wu X-C. Distance to radiation therapy facility influences surgery type among older with early-stage breast cancer, not young women. *Cancer Med*. 2022 Dec 9. PMID: 36495041; PMCID: PMC10067088. doi: 10.1002/cam4.5474
55. Morawski BM, **Hsieh M-C**, Wu M, Sherman R, Mariotto A, Johnson CJ. Determining fitness for use of SEER Cause-specific cause of death in analyses of cause-specific survival. *J Registry Manag*. 2022 Dec 1;49(4):177–189. PMID: 37260823. PMCID: PMC10229190.
56. **Hsieh M-C**, Lefante C, Yi Y, Wu X-C. Racial/Ethnic Disparities in COVID-19 Infection Among Working-Age Women with Precancerous Cervical Lesion. *J Registry Manag*. 2022 Dec 1;49(4): 196-197. PMID: 37260824. PMCID: PMC10229188.
57. Laughlin A, Li T, Yu Q, Wu X-C, Yi Y, **Hsieh M-C**, Shoup M, Chu QD. Impact of Medicaid Expansion on Breast Cancer Diagnosis and Treatment in Southern States. *J Am Coll Surg*. 2023 Apr;236(4):838-845. PMID: 36722711. doi.org/10.1097/XCS.0000000000000550.
58. **Hsieh M-C**, Lefante T, Straif-Bourgeois SC, Yi Y, Gomez N, Shrestha P, Chen VW, Wu X-C. Racial/Ethnic and Socioeconomic Disparities in COVID-19 Infection among Working-Age Women with Precancerous Cervical Lesion: Analysis of More Than Two Years of COVID-19 Data. *Front. Epidemiol*. 2023 May 04; 3. PMID: 38455937. PMCID: PMC10911027. <https://doi.org/10.3389/fepid.2023.1108452>.
59. Tanaka T, Lynch C, Yu K, Morawski B, **Hsieh M-C**, Alverson G, Zimmerman H, Austin AI, Zeng Y and Engels EA. Pancreatic cancer among solid organ transplant recipients in the

- United States. *Journal of Cancer Research and Clinical Oncology*. 2023 Jul;149(7):3325-3333. PMID: 35932302. <https://doi.org/10.1007/s00432-022-04227-3>.
60. Gaffley M, **Hsieh M-C**, Li T, Yi Y, Gibbs J, Wu X-C, Gallagher J, Chu QD. Rural versus urban commuting patients with Stage III Colon Cancer: Is there a difference in treatment and outcome? *Surg Endosc*. 2023 Sep 11. PMID: 37697118. doi: 10.1007/s00464-023-10406-1.
 61. Wu X-C, Yi Y, Maniscalco LS, **Hsieh M-C**, Gruber D, Mendoza L, Subbiah S, Sokol T, Shrestha P, Chen VW, Mederos ET, Ochoa A. Effect of chronic disease on racial difference in COVID-19-associated hospitalization among cancer patients. *J Natl Cancer Inst* . 2023 Oct 9; 115(10):1204-1212. PMID: 37697664 PMCID: PMC10560601. doi: 10.1093/jnci/djad150.
 62. Wang JH, Pfeiffer RM, Musgrove D, Castenson D, Frederickson M, Miller J, Gonsalves L, **Hsieh M-C**, Lynch CF, Zeng Y, Yu KJ, Hart A, Israni AK, Snyder JJ, Engels EA. Cancer mortality among solid organ transplant recipients in the United States during 1987-2018. *Transplantation* 2023 Nov 1;107(11):2433-2442. PMID: 37291711. PMCID: PMC10615843. DOI: 10.1097/TP.0000000000004694
 63. Iyer HS, Shi X, Satagopan JM, Cheng I, Roscoe C, McLaughlin RH, Stroup AM, Soko S, Bandera EV, Hernandez BY, Doherty JA, **Hsieh M-C**, Knowlton R, Qin B, Laden F, Rebbeck TR, Gomez SL. Advancing social and environmental research in cancer registries using address-level data geomasking. *Epidemiol Biomarkers Prev* 2023 Nov. 1;32:1485–9. PMID: 37908192. DOI: 10.1158/1055-9965.EPI-23-0790
 64. Ratnapradipa K, Li T, **Hsieh M-C**, Tenner L, Peters E. Most deprived Louisiana census tracts have higher hepatocellular carcinoma incidence and worse survival. *Frontiers in Oncology*. Sec. Cancer Epidemiology and Prevention. 2024 Feb 5;14. PMID: 38380357. PMCID: PMC10878418. <https://doi.org/10.3389/fonc.2024.1331049>
 65. Zwald F, Sargen M, Austin A, **Hsieh M-C**, Pawlish K, Li J, Lynch CF, Yu K, Engels E. Outcomes in solid organ transplant recipients with a pretransplant diagnosis of melanoma. *Am J Transplant*. 2024 Feb 20;S1600-6135(24)00155-2. PMID: 38387619. <https://doi.org/10.1016/j.ajt.2024.02.013>.
 66. Jackson SS, Pfeiffer RM, **Hsieh M-C**, Li J, Madeleine MM, Pawlish KS, Zeng Y, Yu KJ, Engels EA. Sex differences in cancer incidence among solid organ transplant recipients. *J Natl Cancer Inst*. 2024 Mar 7;116(3):401-407. PMID:37944040. PMCID: PMC10919340. doi: 10.1093/jnci/djad224.
 67. Maramara T, **Hsieh M-C**, Janjua M, Li T, Wu X-C, Williams M, Shoup M, Chu QD. Adherence Rate to ACOSOG Z0011 Based on Breast Cancer Subtypes. *J Am Coll Surg*. 2024 Apr; 238(4): 656-667. PMID: 38193547. <https://doi.org/10.1097/XCS.0000000000000950>
 68. Chu QD, Li T, **Hsieh M**, Yi Y, Gibbs JF, Sahwaneh J, Sang W, Gallagher J, Wu X. Survival Paradox between Stage IIB/C and Stage IIIA Colon Cancer: Is it Time to Revise the American Joint Committee on Cancer TNM System? *Surgical Endoscopy*. 2024 Apr 04; 38:2857–2870. PMID: 38575828. <https://doi.org/10.1007/s00464-024-10723-z>
 69. Venkatesh H, Laughlin A, Li T, Yu Q, Wu X-C, Yi Y, **Hsieh M-C**, Shoup M, Chu QD. Medicaid expansion increases access for rural and impoverished patients with

- pancreatic cancer in southern states. *Ann Surg Oncol*. 2024 May;31(5):2925-2931. PMID: 38361092. <https://doi.org/10.1245/s10434-024-15039-9>.
70. Iyer HS, Stone BV, Roscoe C, **Hsieh M-C**, Stroup A, Wiggins C, Schumacher F, Gomez SL, Rebbeck TR, Trinh Q-D. Access to prostate-specific antigen testing and mortality among men with prostate cancer. *JAMA Network Open*. 2024 June;7(6):e2414582. PMID: 38833252. PMCID: PMC11151156. doi:10.1001/jamanetworkopen.2024.14582.
 71. Escott M, Yi Y, Li T, Foret A, **Hsieh M-C**, Delacroix SE, Gills JR, Wu X-C, Westerman ME. Impact of Rural Location on Receipt of Standard of Care Treatment and Survival for Locally Advanced Bladder Cancer in Louisiana. *Cancer Medicine* 2024 June;13:e7301. PMID: 38923853. PMCID: PMC11199337. <https://DOI.org/10.1002/cam4.7301>.
 72. Shrestha P, **Hsieh M-C**, Ferguson T, Peters ES, Trapido E, Yu Q, Chu QD, Wu X-C. Higher 10-year survival with Breast-Conserving Therapy over Mastectomy for Women with Early-Stage (I-II) Breast Cancer: Analysis of the CDC Patterns of Care Data. *Breast Cancer: Basic and Clinical*. 2024 Sep. 23:18. PMID: 39328281. PMCID: PMC11425729. DOI: 10.1177/11782234241273666
 73. **Hsieh M-C**, Ratnapradipa KL, Rozek L, Wen S, Chu Y-W, Peters ES. Temporal trends and patterns for early- and late-onset adult liver cancer incidence vary by race/ethnicity, subsite, and histologic type in the United States from 2000-2019. *Cancer Causes & Control*, 2025 Jan. 36:551-560. PMID: 39786651. PMCID: PMC11982089. <https://doi.org/10.1007/s10552-024-01955-4>
 74. Tao J, Shing JZ, Yu K, Kreimer AR, **Hsieh M-C**, Pawlish K, Li J, Qiao B, Engels EA. Spectrum of Cancer Risk in Asian American and Pacific Islander Solid Organ Transplant Recipients. *JNCI: Journal of the National Cancer Institute*, 2025, 00(0), 1–9. PMID: 40112042. <https://doi.org/10.1093/jnci/djaf069>
 75. Jackson SS, Pfeiffer RM, Gardner E, **Hsieh M-C**, Insaf T, Lynch CF, Morawski B, Wang S, Yu KJ, Engels EA. Sex differences in cancer survival among solid organ transplant recipients. *Int J Cance* 2025:1-9. PMID: 40347031. <https://doi.org/10.1002/ijc.35415>
 76. Shrestha P, Yu Q, Paters ES, Trapido EJ, **Hsieh M-C**, Ferguson T, Chu Q, Wu X. Socioeconomic disparities in breast cancer survival: Examining potential mediator role of Oncotype DX(ODX) test and stage at diagnosis among HR+/HER2- breast cancer women. *Cancers (Basel)* . 2025 May 28;17(11):1802. PMID: 40507283. PMCID: PMC12153767. doi: 10.3390/cancers17111802.
 77. Gonzalez GV, Danos DM, Ferguson T, **Hsieh M-C**, Therapondos G, Leonardi C. Clinical risk Factors for Hepatocellular Carcinoma in Southeast Louisiana: A Case-control Study. *Cancer Causes & Control*. 2025 June 27. PMID: 40579626. PMCID: PMC10746324. <https://doi.org/10.1007/s10552-025-02021-3>.
 78. Hymel E, Peters ES, Ratnapradipa KL, Zheng C, Allison J, **Hsieh M-C**, Nash SH, Watanabe-Galloway S. Area deprivation and pediatric cancer mortality: An analysis of 2000-2020 state cancer registry data. *Cancer Epidemiol Biomarkers Prev*. 2025 Aug 11. PMID: 40788028. doi: 10.1158/1055-9965.EPI-25-0637.
 79. Korn SM, Dagnino F, Daniels A, Qian Z, Zurl H, Pohl KK, **Hsieh M-C**, Hernandez BY, Piccolini A, Cole AP, Reich AJ, Weissman JS, Trinh Q-D, Iyer H. Travel time to treating facility and mortality in men with prostate cancer. *JAMA Network Open*.

2025;8(12):e2546812. PMID: 41335435. PMCID: PMC12676350.
doi:10.1001/jamanetworkopen.202.46812

80. **Hsieh M-C**, Stoffel EM, Purrington K, Wu X-C, Ahn J, Patil S, Wen S, Jawla M, Mabvakure B, Rozek LS. Effect of Race and Tumor Subsite on Survival Outcome in Early- and Late-Onset Colorectal Cancer. *Cancers*. 2026;18,180. PMID: 41595104. PMCID: PMC12838607. <https://doi.org/10.3390/cancers18020180>.

Submitted Manuscripts:

1. McGee-Avila J, Haas CB, Shing JZ, Lawrence WR, Joe NS, Luo Q, **Hsieh M-C**, Cherala S, Pawlish K, Monterosso A, Cohen C, Hayes J, Callaway BS, Drezner K, Engels EA, Shiels MS. Hepatocellular Carcinoma Survival in People with and without HIV in the United States, 2001-2019 by Dr. Jennifer K McGee-Avila. ***Submitted to The Lancet HIV on July 16, 2025.***
2. Hymel E, Zheng C, Allison J, Ratnapradipa KL, Peters ES, Nash SH, **Hsieh M-C**, Watanabe-Galloway S. Health insurance as a mediator of neighborhood deprivation and pediatric cancer survival: An analysis of state cancer registry data. ***Re-submitted to Cancer Medicine on January 28, 2026.***
3. Dagnino F, Korn S, Daniels D, Qian A, Stelzl D, Zurl H, Pohl K, **Hsieh M-C**, Hernandez BY, Piccolini A, Lughezzani G, Buffi NM, Lipsitz SR, Reich A, Weissman JS, Cole AP, Trinh Q-D, Iyer HS. Association of Travel Burden with Definitive Prostate Cancer Treatment: A United States Registry Cohort Study. ***Submitted to Prostate Cancer and Prostatic Diseases on October 8, 2025.***
4. Suneja G, Henry V, Stephens MJ, Ariotti A, **Hsieh M-C**, Yi Y, Muhsen R, Engels EA, Watt MH, Bartlett J, Ubel P, Fagerlin A. Treatment Decision-Making among Physicians Caring for People Living with HIV and Cancer: A Registry-Linked Survey Study. ***submitted to BMC Health Services Research on October 7, 2025.***
5. Venkatesh H, **Hsieh M-C**, Jyons J, Wu X-C, Chu Q. Is adjuvant chemotherapy necessary for stage IIB/IIC appendiceal adenocarcinoma? ***Submitted to Journal of the American College of Surgeons on December 5, 2025.***
6. Lyons JM, **Hsieh M-C**, Avenzino K, Efishat MA, Chu Q. Do all Stage IA Pancreatic Cancer Patients Need Adjuvant Chemotherapy? ***Submitted to Cancers on February 8, 2026.***
7. Venkatesh H, **Hsieh M-C**, Jyons J, Wu X-C, Chu Q. Is adjuvant chemotherapy necessary for stage IIB/IIC appendiceal adenocarcinoma? ***Submitted to The American Surgeon on February 9, 2026.***
8. Tseng Y-H, Tseng Y-C, Lin Y-H, Chen Y-M, **Hsieh M-C***. Real-World Utilization and Survival Trends of Adjuvant Immunotherapy in Postoperative NSCLC: A Louisiana Population-Based Study. ***Serve as corresponding author. Submitted to the Oncologist on February 25, 2026.***
9. Venkatesh H, **Hsieh M-C**, Nnorom S, Carmona-Tamayo J, Wu X-C, Lyons J, Tee M, Havron W, Chu Q. Adjuvant Chemotherapy and Survival in Stage III Appendiceal Goblet Cell Adenocarcinoma: A Substage-Specific Analysis. ***Submitted to Journal of the American College of Surgeons on February 27, 2026.***

CONCORD Working Group Publications:

1. Claudia Allemani, Hannah K Weir, Helena Carreira, Rhea Harewood, Devon Spika, Xiao-Si Wang, Finian Bannon, Jane V Ahn, Christopher J Johnson, Audrey Bonaventure, Rafael Marcos-Gragera, Charles Stiller, Gulnar Azevedo e Silva, Wan-Qing Chen, Olufemi J Ogunbiyi, Bernard Rachet, Matthew J Soeberg, Hui You, Tomohiro Matsuda, Magdalena Bielska-Lasota, Hans Storm, Thomas C Tucker, Michel P Coleman, and the **CONCORD Working Group**. Global surveillance of cancer survival 1995–2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2). *Lancet*. 2015; 385: 977-1010. Published online: November 26, 2014. DOI: [http://dx.doi.org/10.1016/S0140-6736\(14\)62038-9](http://dx.doi.org/10.1016/S0140-6736(14)62038-9).
2. Audrey Bonaventure, Rhea Harewood, Charles A Stiller, Gemma Gatta, Jacqueline Clavel, Daniela C Stefan, Helena Carreira, Devon Spika, Rafael Marcos-Gragera, Rafael Peris-Bonet, Marion Piñeros, Milena Sant, Claudia E Kuehni, Michael F G Murphy, Michel P Coleman, Claudia Allemani, and the **CONCORD Working Group**. Worldwide comparison of survival from childhood leukaemia for 1995–2009, by subtype, age, and sex (CONCORD-2): a population-based study of individual data for 89 828 children from 198 registries in 53 countries. *The Lancet Haematology*. Published online: April 11, 2017. DOI: [http://dx.doi.org/10.1016/S2352-3026\(17\)30052-2](http://dx.doi.org/10.1016/S2352-3026(17)30052-2).
3. Hannah K. Weir, Sherri L. Stewart, Claudia Allemani, Mary C. White, Cheryl C. Thomas, Arica White, Michel P. Coleman, and the **CONCORD Working Group**. Population-based cancer survival (2001-2009) in the United States: Finding from the CONCORD-2 study. *Cancer*. 2017; 123 (Issue Supplement S24): 4963-4968. DOI: 10.1002/cncr.31028.
4. Claudia Allemani, Tomohiro Matsuda, Veronica Di Carlo, Rhea Harewood, Melissa Matz, Maja Nikšić, Audrey Bonaventure, Mikhail Valkov, Christopher J Johnson, Jacques Estève, Olufemi J Ogunbiyi, Gulnar Azevedo e Silva, Wan-Qing Chen, Sultan Eser, Gerda Engholm, Charles A Stiller, Alain Monnereau, Ryan R Woods, Otto Visser, Gek Hsiang Lim, Joanne Aitken, Hannah K Weir, Michel P Coleman, and the **CONCORD Working Group**. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. *Lancet*. 2018; 391: 1023-1075. Published online January 30, 2018. [http://dx.doi.org/10.1016/S0140-6736\(17\)33326-3](http://dx.doi.org/10.1016/S0140-6736(17)33326-3).

Monographs:

Cancer Incidence in Five Continents, IARC

1. Correa CN, Wu X-C, Andrews PA, **Hsieh M-C**, Lucas HF, Chen VW. Cancer Incidence in Five Continents Vol. VIII, USA Louisiana. IARC Scientific Publications No 155, 2002.
2. Chen VW, Wu XC, Andrews PA, **Hsieh M-C**, Correa CN. Cancer Incidence in Five Continents Vol. IX: USA Louisiana – New Orleans. IARC Scientific Publications No 156, 2007.
3. Chen VW, Wu X-C, **Hsieh M-C**, Andrews PA, Peters ES. Cancer Incidence in Five Continents Vol. X: USA Louisiana – New Orleans. IARC Scientific Publications No 164, 2014.

Cancer in North America

1. *Cancer in North America: 2012-2016 (29th Edition)*

- a. Sherman R, Firth R, De P, Green D, Hofferkamp J, Johnson C, Kohler B, Charlton M, Hofer B, **Hsieh M**, Nash S, Qiao B (eds). *Cancer in North America: 2012-2016. Volume One: Combined Cancer Incidence for the United States, Canada and North America.* Springfield, IL: North American Association of Central Cancer Registries, Inc. May 2019.
- b. Sherman R, Firth R, De P, Green D, Hofferkamp J, Johnson C, Kohler B, Charlton M, Hofer B, **Hsieh M**, Nash S, Qiao B (eds). *Cancer in North America: 2012-2016. Volume Two: Registry-specific Cancer Incidence in the United States and Canada.* Springfield, IL: North American Association of Central Cancer Registries, Inc. May 2019.
- c. Sherman R, Firth R, De P, Green D, Hofferkamp J, Johnson C, Kohler B, Charlton M, Hofer B, **Hsieh M**, Nash S, Qiao B (eds). *Cancer In North America, 2012-2016. Volume Three: Registry-specific Cancer Mortality in the United States and Canada.* Springfield, IL: North American Association of Central Cancer Registries, Inc. May 2019.
- d. Johnson CJ, Wilson R, Sherman R, Firth R, De P, Green D, Hofferkamp J, Kohler B, Charlton M, Hofer B, **Hsieh M**, Nash S, Qiao B (eds). *Cancer in North America: 2012-2016 Volume Four: Cancer Survival in the United States and Canada 2009-2015.* Springfield, IL: North American Association of Central Cancer Registries, Inc. May 2019

2. *Cancer in North America: 2013-2017 (30th Edition)*

- a. Sherman R, Firth R, Charlton M, De P, Green D, Hofer B, Hofferkamp J, **Hsieh M**, Johnson C, Kohler B, Morawski B, Nash S, Qiao B, Wier H (eds). *Cancer in North America: 2013-2017. Volume One: Combined Cancer Incidence for the United States, Canada and North America.* Springfield, IL: North American Association of Central Cancer Registries, Inc. June 2020.
- b. Sherman R, Firth R, Charlton M, De P, Green D, Hofer B, Hofferkamp J, **Hsieh M**, Johnson C, Kohler B, Morawski B, Nash S, Qiao B, Wier H (eds). *Cancer in North America: 2013-2017. Volume Two: Registry-specific Cancer Incidence in the United States and Canada.* Springfield, IL: North American Association of Central Cancer Registries, Inc. June 2020.
- c. Sherman R, Firth R, Charlton M, De P, Green D, Hofer B, Hofferkamp J, **Hsieh M**, Johnson C, Kohler B, Morawski B, Nash S, Qiao B, Wier H (eds). *Cancer In North America, 2013-2017. Volume Three: Registry-specific Cancer Mortality in the United States and Canada.* Springfield, IL: North American Association of Central Cancer Registries, Inc. June 2020.
- d. Johnson C, Wilson R, Sherman R, Firth R, Charlton M, De P, Green D, Hofer B, Hofferkamp J, **Hsieh M**, Kohler B, Morawski B, Nash S, Qiao B, Wier H (eds). *Cancer in North America: 2013-2017. Volume Four: Cancer Survival in the United States and Canada 2010-2016.* Springfield, IL: North American Association of Central Cancer Registries, Inc. June 2020.

3. *Cancer in North America: 2014-2018 (31st Edition)*

- a. Sherman R, Firth R, Charlton M, De P, Green D, Hofer B, Hofferkamp J, **Hsieh M**, Johnson C, Kohler B, Morawski B, Nash S, Qiao B, Wier H (eds). *Cancer in North*

- America: 2014-2018. Volume One: Combined Cancer Incidence for the United States, Canada and North America. Springfield, IL: North American Association of Central Cancer Registries, Inc. May 2021.
- b. Sherman R, Firth R, Charlton M, De P, Green D, Hofer B, Hofferkamp J, **Hsieh M**, Johnson C, Kohler B, Morawski B, Nash S, Qiao B, Wier H (eds). Cancer in North America: 2014-2018. Volume Two: Registry-specific Cancer Incidence in the United States and Canada. Springfield, IL: North American Association of Central Cancer Registries, Inc. May 2021.
 - c. Sherman R, Firth R, Charlton M, De P, Green D, Hofer B, Hofferkamp J, **Hsieh M**, Johnson C, Kohler B, Morawski B, Nash S, Qiao B, Wier H (eds). Cancer In North America, 2014-2018. Volume Three: Registry-specific Cancer Mortality in the United States and Canada. Springfield, IL: North American Association of Central Cancer Registries, Inc. May 2021.
 - d. Johnson C, Wilson R, Sherman R, Firth R, Charlton M, De P, Green D, Hofer B, Hofferkamp J, **Hsieh M**, Kohler B, Morawski B, Nash S, Qiao B, Wier H (eds). Cancer in North America: 2014-2018 Volume Four: Cancer Survival in the United States and Canada 2011-2017. Springfield, IL: North American Association of Central Cancer Registries, Inc. May 2021.
4. ***Cancer in North America: 2015-2019 (32nd Edition)***
- a. Sherman R, Firth R, Kahl A, De P, Green D, Hofer B, Liu L, **Hsieh M**, Johnson C, Kohler B, Morawski B, Nash S, Qiao B, Wier H (eds). Cancer in North America: 2015-2019. Volume One: Combined Cancer Incidence for the United States, Canada and North America. Springfield, IL: North American Association of Central Cancer Registries, Inc. May 2022.
 - b. Sherman R, Firth R, Kahl A, De P, Green D, Hofer B, Liu L, **Hsieh M**, Johnson C, Kohler B, Morawski B, Nash S, Qiao B, Wier H (eds). Cancer in North America: 2015-2019. Volume Two: Registry-specific Cancer Incidence in the United States and Canada. Springfield, IL: North American Association of Central Cancer Registries, Inc. May 2022.
 - c. Sherman R, Firth R, Kahl A, De P, Green D, Hofer B, Liu L, **Hsieh M**, Johnson C, Kohler B, Morawski B, Nash S, Qiao B, Wier H (eds). Cancer In North America, 2015-2019. Volume Three: Registry-specific Cancer Mortality in the United States and Canada. Springfield, IL: North American Association of Central Cancer Registries, Inc. May 2022.
 - d. Johnson C, Wilson R, Mariotto A, Morawski B, Weir H, Firth R, Sherman R, Kahl A, De P, Hofer B, **Hsieh M**, Liu L, Nash S, Qiao B (eds). Cancer in North America: 2015-20189 Volume Four: Cancer Survival in the United States and Canada 2012-2018. Springfield, IL: North American Association of Central Cancer Registries, Inc. May 2022.

Cancer in Louisiana

1. Wu XC, Correa CN, Andrews PA, **Hsieh M-C**, Schmidt BA, Ahmed MN, Chen VW (eds). *Cancer Incidence and Mortality in Louisiana, 1993-1997*. New Orleans: Louisiana Tumor Registry, 2001. (*Cancer in Louisiana*; vol. 13.)
2. Chen VW, Schmidt BA, Wu XC, Correa CN, Andrews PA, **Hsieh M-C**, Ahmed MN (eds). *Childhood Cancer in Louisiana, 1988-1996*. New Orleans: Louisiana Tumor Registry, 2001. (*Cancer in Louisiana*; vol. 14.)
3. Andrews PA, Correa CN, Wu XC, **Hsieh M-C**, Schmidt BA, Chen VW (eds). *Cancer Incidence and Mortality in Louisiana, 1994-1998*. New Orleans: Louisiana Tumor Registry, 2002. (*Cancer in Louisiana*; vol. 15.)
4. Correa CN, Wu XC, Andrews PA, **Hsieh M-C**, Chen VW (eds). *Cancer Incidence and Mortality in Louisiana, 1995-1999*. New Orleans: Louisiana Tumor Registry, 2003. (*Cancer in Louisiana*; vol. 16.)
5. Correa CN, Wu XC, Andrews PA, **Hsieh M-C**, Chen VW (eds). *Cancer in Louisiana, 1996-2000*. New Orleans: Louisiana Tumor Registry, 2003. (*Cancer in Louisiana*; vol. 17.)
6. Correa CN, Wu XC, Andrews PA, **Hsieh M-C**, Chen VW (eds). *Cancer in Louisiana, Parish Profiles Cancer Incidence 1988-2000*. New Orleans: Louisiana Tumor Registry, 2004. (*Cancer in Louisiana*; vol. 18.)
7. **Hsieh M-C**, Andrews PA, Wu XC, Correa CN, Huang SL, Chen L, Lucas HF, and Chen VW (eds). *Cancer Incidence and Mortality in Louisiana, 1997-2001*, New Orleans: Louisiana Tumor Registry, 2005. (*Cancer in Louisiana*; vol. 19.)
8. **Hsieh M-C**, Andrews PA, Wu XC, Correa CN, Huang SL, Chen L, Lucas HF, and Chen VW (eds). *Cancer Incidence and Mortality in Louisiana, 1998-2002*, New Orleans: Louisiana Tumor Registry, 2006. (*Cancer in Louisiana*; vol. 20.)
9. **Hsieh M-C**, Andrews PA, Wu XC, Chen L, Huang SL, Peters ES, and Chen VW (eds). *Cancer Incidence and Mortality in Louisiana, 1999-2003*, New Orleans: Louisiana Tumor Registry, 2006. (*Cancer in Louisiana*; vol. 21.)
10. Peters ES, Schmidt BA, Andrews PA, **Hsieh M-C**, Wu XC, and Chen VW (eds). *Cancer Incidence and Mortality in Louisiana, 2000-2004*, New Orleans: Louisiana Tumor Registry, 2007. (*Cancer in Louisiana*; vol. 22.)
11. Andrews PA, **Hsieh M-C**, Mumphrey B, Pareti LA, Schmidt BA, Namiak M, Schmidt BA, Peters ES, Wu XC, and Chen VW (eds). *Cancer Incidence and Mortality in Louisiana, 2001-2005*, New Orleans: Louisiana Tumor Registry, 2008. (*Cancer in Louisiana*; vol. 23.)
12. Andrews PA, **Hsieh M-C**, Mumphrey B, Pareti LA, Namiak M, Schmidt BA, Peters ES, Wu XC, Chen VW (eds), *Cancer Incidence and Mortality in Louisiana, 2002-2006*, New Orleans: Louisiana Tumor Registry, 2010. (*Cancer in Louisiana*; vol. 24.)
13. **Hsieh M-C**, Mumphrey B, Pareti LA, Namiak M, Schmidt BA, Andrews PA, Peters ES, Wu XC, Chen VW (eds), *Cancer Incidence and Mortality in Louisiana, 2003-2007*, New Orleans: Louisiana Tumor Registry, 2011. (*Cancer in Louisiana*; vol. 25.)
14. Wu XC, Andrews PA, **Hsieh M-C**, Pareti LA, Mumphrey B, Namiak M, Schmidt BA, Chen VW (eds), *Cancer Incidence and Mortality in Louisiana, 2004-2008*, New Orleans: Louisiana Tumor Registry, 2011. (*Cancer in Louisiana*; vol. 26.)
15. Andrews PA, **Hsieh M-C**, Pareti LA, Mumphrey B, Li X, Schmidt BA, Ferguson DB, Lefante C, Maniscalco LS, Wu X, Chen VW (eds). *Cancer in Louisiana, 2005-2009*. New Orleans: Louisiana Tumor Registry, 2012. (*Cancer in Louisiana*; Vol. 27.)

16. Andrews PA, **Hsieh M-C**, Maniscalco LS, Pareti LA, Mumphrey B, Li X, Schmidt BA, Ferguson DB, Lefante C, Landry I, Li X, Wu X, Chen VW (eds). Cancer in Louisiana, 2006-2010. New Orleans: Louisiana Tumor Registry, 2013. (*Cancer in Louisiana*; Vol. 28.)
17. **Hsieh M-C**, Andrews PA, , Maniscalco LS, Pareti LA, Mumphrey B, Schmidt BA, Lefante C, Ferguson DB, Li X, Chen VW, Landry I, Wu X (eds). Cancer in Louisiana, 2007-2011. New Orleans: Louisiana Tumor Registry, 2014. (*Cancer in Louisiana*; Vol. 29.)
18. Maniscalco LS, Lefante C, **Hsieh M-C**, Andrews PA, , Pareti LA, Mumphrey B, Schmidt BA, Ferguson DB, Li X, Chen VW, Landry I, Wu X (eds). Cancer in Louisiana, 2008-2012. New Orleans: Louisiana Tumor Registry, 2015. (*Cancer in Louisiana*; Vol. 30.)
19. Maniscalco L, Lefante C, **Hsieh M-C**, Andrews P, Pareti L, Mumphrey B, Ferguson D, Schmidt B, , Li X, Peterson L, O'Flarity M, Lynch MA, Wu X (eds). Cancer in Louisiana, 2009-2013. New Orleans: Louisiana Tumor Registry, 2016. (*Cancer in Louisiana*; Vol. 31.)
20. Maniscalco L, Lefante C, Rosales C, Zhang L, **Hsieh M-C**, Pareti L, Mumphrey B, Lynch MA, Wu XC (eds). Cancer in Louisiana, 2010-2014. New Orleans: Louisiana Tumor Registry, 2017. (*Cancer in Louisiana*; Vol. 32.)
21. Wu XC, Maniscalco L, Zhang L, Yi Y, Lefante C, Ricks L, Straif-Bourgeois S, **Hsieh M-C** (eds). Cancer Incidence in Louisiana by Census Tract, 2006-2014. New Orleans, Louisiana Tumor Registry, 2018.
22. Maniscalco L, French J, Rosales C, Lefante C, **Hsieh M-C**, Zhang L, Pareti L, Mumphrey B, Lynch MA, Wu XC (eds). Cancer in Louisiana, 2011-2015. New Orleans: Louisiana Tumor Registry, 2018. (*Cancer in Louisiana*; Vol. 33.)
23. Maniscalco L, Zhang L, Yi Y, Lefante C, Rosales C, Hsieh M-C, Wu XC (eds). Cancer Incidence in Louisiana by Census Tract, 2005-2015. New Orleans, Louisiana Tumor Registry, March 2019.
24. Maniscalco L, Rosales C, Lefante C, Hsieh MC, Yi Y, Pareti L, Mumphrey B, Lynch MA, and Wu XC (eds). Cancer in Louisiana, 2012-2016. New Orleans: Louisiana Tumor Registry, 2019. (*Cancer in Louisiana*; Vol. 34.)
25. Maniscalco L, Yi Y, Zhang L, Lefante C, **Hsieh MC**, Wu XC (eds). Cancer Incidence in Louisiana by Census Tract, 2007-2016. New Orleans: Louisiana Tumor Registry, March 2020.
26. Maniscalco L, Lefante C, **Hsieh MC**, Yi Y, Pareti L, Mumphrey B, Lynch MA, and Wu XC (eds). Cancer in Louisiana, 2013-2017. New Orleans: Louisiana Tumor Registry, 2020. (*Cancer in Louisiana*; Vol. 35)
27. Maniscalco L, Yi Y, Lefante C, **Hsieh MC**, Wu XC (eds). Cancer Incidence in Louisiana by Census Tract, 2008-2017. New Orleans: Louisiana Tumor Registry, March 2021.
28. Maniscalco L, Lefante C, **Hsieh MC**, Yi Y, Pareti L, Mumphrey B, Lynch MA, and Wu XC (eds). Cancer in Louisiana, 2014-2018. New Orleans: Louisiana Tumor Registry, 2021. (*Cancer in Louisiana*; Vol. 36.)
29. Maniscalco L, Yi Y, Lefante C, **Hsieh MC**, Wu XC (eds). Cancer Incidence in Louisiana by Census Tract, 2009-2018. New Orleans: Louisiana Tumor Registry, March 2022.
30. Maniscalco L, **Hsieh MC**, Lefante C, Yi Y, Pareti L, Mumphrey B, Lynch MA, and Wu XC (eds). Cancer in Louisiana, 2015-2019. New Orleans: Louisiana Tumor Registry, August 2022. (*Cancer in Louisiana*; Vol. 37.)

31. Maniscalco L, Yi Y, Lefante C, Mumphrey B, Kinchen JW, **Hsieh MC**, Wu XC (eds). Cancer Incidence in Louisiana by Census Tract, 2010-2019. New Orleans: Louisiana Tumor Registry, March 2023.
32. Maniscalco L, **Hsieh MC**, Lefante C, Yi Y, Pareti L, Mumphrey B, Lynch MA, and Wu XC (eds). Cancer in Louisiana, 2016-2020. New Orleans: Louisiana Tumor Registry, September 2023. (Cancer in Louisiana; Vol. 38.)
33. Maniscalco L, Yi Y, Lefante C, Mumphrey B, Wahner I, **Hsieh MC**, Wu XC (eds). Cancer Incidence in Louisiana by Census Tract, 2011-2020. New Orleans: Louisiana Tumor Registry, March 2024.
34. Maniscalco L, **Hsieh MC**, Lefante C, Yi Y, Pareti L, Mumphrey B, Lynch MA, and Wu XC (eds). Cancer in Louisiana, 2017-2021. New Orleans: Louisiana Tumor Registry, October 2024. (Cancer in Louisiana; Vol. 39.)
35. Maniscalco L, Yi Y, Wagner I, Lefante C, Mumphrey B, **Hsieh MC**, Wu XC (eds). Cancer Incidence in Louisiana by Census Tract, 2012-2021. New Orleans: Louisiana Tumor Registry, March 2025.
36. Maniscalco L, **Hsieh MC**, Lefante C, Yi Y, Pareti L, Mumphrey B, Lynch MA, and Wu XC (eds). Cancer in Louisiana, 2018-2022. New Orleans: Louisiana Tumor Registry, October 2025. (Cancer in Louisiana; Vol. 40.)

Cancer Coding Manual and Tool

1. NAACCR Race and Ethnicity Work Group. NAACCR Asian Pacific Islander Identification Algorithm [NAPIIA v1.2.1]. Springfield, IL: North American Association of Central Cancer Registries, August 2011. https://www.naacr.org/wp-content/uploads/2016/11/NAPIIA_v1_2_1_08122011.pdf
2. NAACCR Data Item Consolidation Manual. 2015. <https://www.naacr.org/wp-content/uploads/2016/11/2015-Data-Item-Consolidation-Manual-PDF.pdf>

ABSTRACTS AND PRESENTATIONS AT PROFESSIONAL CONFERENCES

1. Correa CN, Chen VW, Wu XC, **Hsieh MC**. *Cancer incidence in the industrial corridor-Louisiana*. Presented at the annual meeting of North American Association of Central Cancer Registries, Miami, FL, June 2001.
2. Wu XC, Chen VW, Andrews PA, Ma L, **Hsieh MC**, et al. *Assessing recommended treatment for stage III colon cancer, utilizing current cancer registry data*. Presented at the annual meeting of North American Association of Central Cancer Registries, Hawaii, June 2003.
3. **Hsieh MC**, Chen VW, Wu XC, Nyirenda C, Huang SL, Correa CN, Schmidt BA. *Evaluation of NAACCR Hispanic identification algorithm (NHIA) for cancer registry data: the Louisiana experience*. Presented at the annual meeting of North American Association of Central Cancer Registries, Utah, June 2004.
4. Wu XC, Chen VW, Chen LS, **Hsieh MC**, Schmidt BA, Andrews PA. *Trends in Surgery and Adjuvant Treatments for Patients diagnosed with Stage I and II Prostate Cancer in Louisiana*. Presented at the annual meeting of North American Association of Central Cancer Registries, Utah, June 2004.

5. Schymura MJ, Kahn AR, German RR, **Hsieh MC**, Richardson LC, NPCR POC1 Study Group. *Factors Associated with Initial Treatment for Clinically Localized Prostate Cancer*. Presented at the annual meeting of North American Association of Central Cancer Registries, Regina, Saskatchewan, Canada, June 13-15, 2006.
6. **Hsieh MC**, Pareti LA, Namiak MT, Andrew PA, Wu XC, Chen VW. *Innovative Quality Assurance Activities Improve Registry Data Quality*. Presented at the annual meeting of North American Association of Central Cancer Registries, Michigan, June 2007.
7. Schymura MJ, Boscoe FP **Hsieh, M-C**, Williams MA, Henry K. *Working with Asian and Pacific Islander Data: II. Coding Issues with Pacific Islanders*. Presented at the annual meeting of North American Association of Central Cancer Registries, Michigan, June 2007.
8. **Hsieh MC**, Wu XC, Whitaker LM, Pareti LA., Peters ES, Andrews PA, Chen VW. *Disparity in Lymph Node Evaluation, a Contributing Factor for Colon Cancer Survival Differences in Louisiana*. Presented at the Xavier University of Louisiana College of Pharmacy's 2nd Annual Health Disparities Conference, New Orleans, April 2008. Poster
9. Chen VW, Wu XC, Andrews PA, **Hsieh MC**, Li XR, Whitaker LM. *Racial Disparities in Incidence, Mortality, Stage, and Survival of Female Breast Cancer in Louisiana*. Presented at the Xavier University of Louisiana College of Pharmacy's 2nd Annual Health Disparities Conference, New Orleans, April 2008. Poster.
10. Wu XC, Li XR, Whitaker LM, **Hsieh MC**, Andrews PA, Chen VW. *Racial Disparities in Incidence, Mortality, Stage, and Survival of Cervical Cancer in Louisiana*. Presented at the Xavier University of Louisiana College of Pharmacy's 2nd Annual Health Disparities Conference, New Orleans, April 2008. Poster
11. Peters ES, Luckett BG, Schmidt, BA **Hsieh MC**, Chen VW. *Geographic Assessment of Breast Cancer in Louisiana*. Presented at the Xavier University of Louisiana College of Pharmacy's 2nd Annual Health Disparities Conference, New Orleans, April 2008. Poster Presentation.
12. **Hsieh MC**, Pareti LA, Chen VW. *Using NAPIIA to Improve the Accuracy of Asian Race Code in Registry Data*. Presented at the NAACCR Annual Conference, Denver CO, June 2008.
13. Whitaker LM, **Hsieh MC**. *Dead or Alive? Determining Vital Status with Social Security Death Master File (SSDMF) Linkages*. . Presented at NAACCR Annual Conference, Denver, June 2008. Poster
14. **Hsieh MC**, Wu XC, Andrews PA, Chen VW. ***Incidence of Soft Tissue Sarcoma in Older Adolescents and Young Adults, United States, 1995-2004***. Presented at NAACCR Annual Conference, San Diego CA, June 2009. Poster **Received the first place in Data Quality/Registry Operations and Management**.
15. **Hsieh MC**, Velasco C, Wu XC, Pareti LA, Andrews PA, Chen VW. *Influence of Socioeconomic Status and Hospital Type on Disparities of Lymph Node Evaluation in Colon Cancer Patients*. Presented at NAACCR Annual Conference, Louisville KY, June 2011.
16. Yu Q, Wu XC, **Hsieh MC**, Fan Y, Andrews PA, Wohler B, Huang B, Qiao B, Jemal A, Ajani UA. *Cancer Data Quality Control by Proportion of Unknown Stage - Data Assessment Workgroup #1*. Presented at NAACCR Annual Conference, Louisville KY, June 2011.

17. Huang B, Wohler B, Wu XC, Yu Q, Qiao B, Andrews PA, Ajani UA, Jemal A, **Hsieh MC**, Shelton B. *Benign/Borderline Intracranial and Central Nervous System Tumors in CINA Deluxe Data – Data Assessment Workgroup #2*. Presented at NAACCR Annual Conference, Louisville KY, June 2011.
18. Wohler B, Qiao B, Schymura MJ, Wu XC, , Andrews PA, **Hsieh MC**, Huang B, Yu Q, Ajani UA, Jemal A. *Data Quality of Surgery and Radiation for Four Major Cancer Sites in CINA Deluxe – Data Assessment Workgroup #3*. Presented at NAACCR Annual Conference, Louisville KY, June 2011.
19. Wohler B, Wu XC, Andrews PA, Huang B, Qiao B, **Hsieh MC**, Ajani UA, Jemal A, Yu Q. *Data Quality of Tumor Size and Depth for Breast Cancer and Melanoma in CINA Deluxe – Data Assessment Workgroup #4*. Presented at NAACCR Annual Conference, Louisville KY, June 2011.
20. **Hsieh MC**, Wu XC, Wohler B, Andrews PA, Yu Q, Qiao B, Jamison M, Jemal A, Huang B, Ajani UA, Schymura MJ. Evaluating Unknown Stage by Collaborative Staging Components and Surgical Status for Colon Cancer – Data Assessment Workgroup. Presented at NAACCR Annual Conference, Portland OR, June, 2012
21. Wohler B, **Hsieh MC**, Wu XC, Jamison M, Qiao B, Huang B, Andrews PA, Yu Q, Jemal A, Ajani UA. Template Assessing Data Quality for CINA Deluxe. Presented at NAACCR Annual Conference, Portland OR, June, 2012
22. Chen VW, **Hsieh MC**, Pareti LA, Wu XC. Assessing Completeness of CSV2 Site Specific Factor Data Items in Louisiana. Presented at NAACCR Annual Conference, Portland OR, June, 2012
23. Chen VW, Wu XC, Andrews PA, **Hsieh MC**, Mumphrey B, Lefante CM, Namiak M, Pareti LA, Schmidt BA. Building Bridges with Hospital Registries: Louisiana Experience. Presented at NAACCR Annual Conference, Portland OR, June, 2012
24. **Hsieh MC**, Pareti LA, O’Flarity M, Nguyen Q, Chen VW. Impact of Comorbidities on Treatment Choice for Colon Cancer Patients, Louisiana-CDC CER project. Presented at NAACCR Annual Conference, Austin TX, June, 2013
25. Li X, Wu XC, Kruchko C, **Hsieh MC**, Andrews PA, Huang B, Wohler B, Qiao B, Jamison M. Are Benign and Borderline Brain Tumors Underreported? Presented at NAACCR Annual Conference, Austin TX, June, 2013
26. Lefante C, **Hsieh M**, Danos D, Yang S, Li X, WU X, Chen V. Constructing A Process for Utilizing Insurance Claims Data: The Use of Medicaid Derived Treatment as A Launching Pad. Presented at NAACCR Annual Conference, Austin TX, June, 2013
27. Landry I, Wu X, **Hsieh M**, Chen VW. *Timely and Complete Capture of Pediatric and Young Adult Cancer Cases in Louisiana: A Comprehensive Approach*. Presented at NAACCR Annual Conference, Austin TX, June, 2013
28. **Hsieh MC**, Chiu YW, Velasco V, Wu XC, O’Flarity M, Chen VW. *Impact of Race/Ethnicity and Socioeconomic Status on Adjuvant Chemotherapy Use among Elderly Patients with Stage III Colon Cancer*. Presented at NAACCR Annual Conference, Ottawa Canada. June 2014.
29. Li XR, Wu XC, Andrews PA, **Hsieh MC**, Chen VW. *Improving Completeness of Benign Brain Tumor Reporting by a Linkage with Hospital Inpatient Discharge Data - Louisiana*

- Tumor Registry's Experiences*. Presented at NAACCR Annual Conference, Ottawa Canada. June 2014
30. Ries LG, Chen VW, **Hsieh M**, Lynch C, Cronin K, Edwards BK. *Evaluation of New clinically-Significant Factors in Collaborative Stage for Female Breast Cancer, SEER 2010 Diagnoses*. Presented at the annual meeting of IARC, Ottawa Canada. June 2014
 31. Chen VW, Wu XC, Andrews PA, **Hsieh MC**. *Use of Cancer Surveillance Data for Entire Cancer Control Continuum*. Presented at the annual meeting of International Association of cancer Registries, Ottawa Canada. June 2014
 32. Karlitz JJ, **Hsieh MC**, Liu Y, Blanton C, Schmidt B, Jessup JM, Wu XC, Chen VW. *Population-based Lynch Syndrome Screening by Microsatellite Instability in Patients \leq 50: Prevalence, Testing Determinants and Result Availability Prior to Colon Surgery*. American College of Gastroenterology (ACG) meeting. Philadelphia PA. October 2014.
 33. **Hsieh MC**, Yu Q, Lefante J, Lefante C, Chen VW. *Multiple Mediation Analysis with Survival Data: An Application to Analyze Racial Disparity in Stage III Colon cancer Survival*. Presented at NAACCR Annual Conference, Charlotte, NC. June 2015.
 34. **Hsieh MC**, Thompson T, Chen VW, O'Flarity MB, Wu XC, Morris C, Styles T. *The Effect of Comorbidity on the Use of Adjuvant Chemotherapy and Type of Regimen for Resected Stage III Colon Cancer Patients*. Presented at NAACCR Annual Conference, Charlotte, NC. June 2015.
 35. Sineshaw HM, **Hsieh MC**, Li X, Wohler-Torres B, Qiao B, Huang B, Jemal A, Sherman R, Wu M, Yu Q, Wu X. *Evaluation of Completeness of Lymph Node Count in the North American Association of Central Cancer Registries for Selected Cancers*. Presented at NAACCR Annual Conference, Charlotte, NC. June 2015.
 36. Wu XC, Thompson T, **Hsieh M**, Zhou M, Andrews P, Loch M, Styles T, Chen VW. *Nonclinical Factors Associated with Premature Termination of Adjuvant Chemotherapy for Stage I-III Breast Cancer*. Presented at NAACCR Annual Conference, Charlotte, NC. June 2015.
 37. Chen VW, Karlitz JJ, Loch MM, **Hsieh MC**, Andrews PA, O'Flarity MB, Li XR, Zhang L, Wu XC. *Using Enhanced Registry Data for Clinical Management and Cancer Care*. Presented at NAACCR Annual Conference, Charlotte, NC. June 2015.
 38. Rico A, Thompson T, Chen V, Wu X, **Hsieh M**, Karlitz J, West D. *An In-Depth Study of KRAS Biomarker Testing in Colorectal Cancer Patients*. Presented at the annual meeting of North American Association of Central Cancer Registries, Charlotte, NC. June 2015.
 39. Zhang L, Ferguson T, Wu X-C, **Hsieh M-C**, Fontham E, Loch M, Yu Q, Chen V. *Frequency and predictors of insufficient chemotherapy use among stage I-III breast cancer patients by molecular subtype*. Presented at 2015 Breast Cancer Symposium. San Francisco, CA. September 25-257, 2015.
 40. Loch M, Zhang L, **Hsieh MC**, Wu XC and Chen VW. *A statewide, population-based study of molecular subtypes of female breast cancer: Treatment and associated factors*. Presented at the 38th Annual CTSC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016; 76(4 Suppl): Abstract nr P1-07-14. February 2016. DOI: 10.1158/1538-7445.SABCS15-P1-07-14

41. Loch M, Li XG, **Hsieh MC**, Wu XC, and Chen VW. New Orleans has the highest incidence rates of triple negative breast cancer. Presented at 38th Annual CTBC-AACR San Antonio Breast Cancer Symposium. San Antonio TX, December 8-12, 2015. Abstract nr P1-09-04.
42. **Hsieh MC**, Mumphrey B, Pareti L, Wu XC. Innovative Approach to Improve Completeness of Treatment in Cancer Registry Data. Poster Presentation, NAACCR Annual Conference. St. Louis, MO. June 14-16, 2016.
43. Wu XC, Li XR, Petkov V, **Hsieh MC**, Andrews PA, Chen VW. Utilization of Oncotype DX Test for Node-Negative, Hormone Receptor Positive, Her2 Negative Breast Cancer in the Community Setting. Presented at NAACCR Annual Conference. St. Louis, MO. June 14-16, 2016.
44. Lefante C, **Hsieh MC**, Wu XC. Utilizing State databases to Improve Follow-up: The Louisiana Vaccination Experience. Presented at NAACCR Annual Conference. St. Louis, MO. June 14-16, 2016.
45. Lynch M, Landry I, B Mumphrey, **Hsieh MC**, Wu XC, Chen VW. Improving Patient demographics in E-Path Reports and Timely Capture of Clinically Diagnosed cancer cases by Linkage with Hospitals Admission, Discharge, and Transfer (ADT) data. Presented at NAACCR Annual Conference. St. Louis, MO. June 14-16, 2016.
46. Qiao B, Schymura M, Wu X, Wohler-Torres B, **Hsieh MC**, Huang B, Wu M, Yu Q, Sineshaw HM, Sherman R, Kruchko C, Li X, Jemal A. Multiple Primary cancers in the United States, 2007-2011. Poster Presentation. NAACCR Annual Conference. St. Louis, MO. June 14-16, 2016.
47. Zhang L, King J, Ferguson T, Wu X-C, **Hsieh M-C**, Chen VW. Socioeconomic status influences the utilization of chemotherapy differently between white and black triple negative breast cancer patients. Presented at Society of Epidemiologic Research (SER) as a poster presentation. Miami, FL, June 21-24, 2016
48. Yu Q, Wu X-C, **Hsieh M-C**, Ferguson T, Scribner RA. Mediation Analysis to Explore Racial Disparities in Breast Cancer Survival. Poster presentation. 10th Anniversary Health Disparities Conference. March 16–17, 2017 in New Orleans, LA.
49. Riley CA, Wu EL, **Hsieh M-C**, Marino MJ, Wu X-C, McCoul ED. Gastroesophageal reflux as a precursor to malignancy of the upper aerodigestive tract in the United States. Presented at the Triological Society Annual Meeting at COSM in San Diego, CA, April 28-30, 2017.
50. Wu M, **Hsieh MC**, Huang B, Jemal A, Kruchko C, Li X, Qiao B, Sherman R, Sineshaw H, Wohler B, Wu X, Yu Q. Breast cancer biomarker data quality evaluation among Central Cancer Registries in the US, 2010-2013. Presented at NAACCR Annual Conference, Albuquerque, NM, June 22, 2017.
51. Yi Y, **Hsieh M-C**, Li X, Wu X-C. The Completion of Chronic Comorbidity Reporting from Hospital Inpatient Discharge Data Varies by Observed Time Windows. Poster Presentation. NAACCR Annual Conference, Albuquerque, NM, June 20-22, 2017.
52. Abastillas G, Lam C, Petkov V, Adamo P, Coyle L, Stevens J, Wu X-C, **Hsieh M-C**, Negoita S. Data Quality Audit on Melanoma Tumor Depth. Poster presentation. NAACCR Annual Conference, Albuquerque, NM, June 20-22, 2017.

53. Crawford A, Benard VB, Greek A, Stroup A, Herman N, **Hsieh M-C**, Alverson G, O'Flarity M, Huh W, Jackson JE. The Case Investigation of Cervical Cancer (CICC) Study: Chart Abstraction from Primary and Specialty Care Providers 5 Years Prior to Patient Diagnosis. Poster presentation. NAACCR Annual Conference, Albuquerque, NM, June 20-22, 2017.
54. Yu Q, Wu X, **Hsieh M**, Li B, Scribner RA. Explore Racial Disparities in Breast Cancer Survival Using Nonlinear Mediation Analysis. Accepted. The Western North American Region of the international Biometric Society, Santa Fe, NM. June 25-28, 2017.
55. Marino MJ, **Hsieh M-C**, Wu EL, Riley CA, Wu X-C, McCoul ED. Screening for Nasopharyngeal and Paranasal Sinus Cancer. Presented at American Academy of Otolaryngology–Head and Neck Surgery Foundation (AAO-HNSF) 2017 Annual Meeting & OTO Experience. Chicago, IL. September 10-13, 2017.
56. **Hsieh M-C**, Pareti L, Mumphrey B, Pappas N, Yi Y, Lefante C, Wu X-C. Central Cancer Registry Data Quality Improvement: Routine and Innovative Approaches. Presented at 2018 National Cancer Registrars Association (NCRA) Annual Educational Conference. New Orleans, LA. May 23, 2018.
57. **Hsieh M-C**, Pappas N, Pareti L, Mumphrey B, Peterson, Yi Y, Wu X-C. Evaluating Coding Completeness and Accuracy – Reabstraction Audit. Poster Presentation at 2018 NCRA Annual Educational Conference. New Orleans, LA. May 21-23, 2018.
58. Lefante C, Yi Y, **Hsieh M-C**, Wu X-C. Using the State's Hospital Inpatient Discharge Data to Aid Death Clearance Follow-Back. Presented at 2018 NCRA Annual Educational Conference. New Orleans, LA. May 21-23, 2018.
59. Yi Y, **Hsieh M-C**, Wu X-C. Hospital Inpatient Discharge Data Helps Improve the Comorbidity and Insurance Information in Cancer Registry Data. Poster Presentation at 2018 NCRA Annual Educational Conference. New Orleans, LA. May 21-23, 2018.
Received the First Place Award.
60. **Hsieh M**, Zhang L, Wu X, O'Flarity M, Loch M, Chen VW. The Association of Breast Cancer Subtypes, Guideline-Concordant Treatment and Survival among Patients with Stage I-III Disease. Presented at NAACCR 2018 Annual Conference. Pittsburg PA, June 12-14, 2018.
61. **Hsieh M**, Kruchko C, Sherman R, Huang B, Wu M, Sineshaw H, Qiao B, Yu Q, Wu X. Evaluating the Completeness of WHO Grade for Brain and Central Nervous System Tumors in the US, 2010-2014. Presented at NAACCR 2018 Annual Conference. Pittsburg PA, June 12-14, 2018.
62. Maniscalco L, Rosales C, Yi Y, **Hsieh M**, Scoppa S, Yu M, Wu XC. Producing Cancer Statistics at the Census Tract Level: A Louisiana Story. Poster Presentation at NAACCR 2018 Annual Conference. Pittsburg PA, June 12-14, 2018. **Received the Second Place Award.**
63. Riley CA, Marino MJ, **Hsieh M-C**, Wu EL, Wu X-C, McCoul ED. Detection of laryngeal carcinoma in the U.S. elderly population with gastroesophageal reflux disease. AAO-HNSF 2018 Annual Meeting & OTO Experience. Atlanta, GA. October 7-10, 2018
64. Yu Q, Zhang L, **Hsieh M**, Wu X, Scribner R, Li B. Regularized multiple mediation analysis for big data set—With an application to explore racial disparity in breast cancer survival [abstract]. In: Proceedings of the Eleventh AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2018 Nov

- 2-5; New Orleans, LA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2020;29(6 Suppl):Abstract nr C020.
65. Zhang L, **Hsieh M-C**, Petkov V, Yu Q, Wu X-C. Trend of utilization of Oncotype DX testing among female hormone receptor positive breast cancer patients in 14 SEER registries, 2004-2015. Poster Presentation at 41st Annual CTRC-AACR San Antonio Breast Cancer Symposium. San Antonio TX, December 4-8, 2018. Abstract nr P3-12-20.
 66. Zhang L, **Hsieh M-C**, Petkov V, Wu X-C, Yu Q. Utilization and survival benefit of radiation therapy among hormone receptor positive breast cancer patients with recurrence score from Oncotype DX testing. Poster Presentation at 41st Annual CTRC-AACR San Antonio Breast Cancer Symposium. San Antonio TX, December 4-8, 2018. Abstract nr P3-12-23.
 67. Zhang L, **Hsieh M-C**, Yu Q, Wu X-C. Racial differences in the risk of secondary bladder cancer following radiation therapy among prostate cancer patients. Poster presentation at AACR 2019 conference, Atlanta, GA, March 27 – April 2, 2019. Abstract #:4204
 68. **Hsieh M-C**, Van Dyne E, Lefante C, Shapiro JA, Lynch MA, Pordell P, Gomez N, Mumphrey B, Maniscalco L, Jetly-Shridhar R, Wu X-C. Evaluating the utilization of Lower Anogenital Squamous Terminology (LAST) two-tiered classification for preinvasive cervical cancer and its impact on reporting in a population-based cancer registry. Oral presentation at NAACCR 2019 Annual Conference. Vancouver, BC, Canada, June 13, 2019
 69. Lefante C, Wu X-C, **Hsieh M-C**, Mumphrey B. Louisiana's hospital follow-up exchange: A decade of partnership. Oral presentation at NAACCR 2019 Annual Conference. Vancouver, BC, Canada, June 11, 2019
 70. Lynch MA, Wu X-C, Mumphrey B, **Hsieh M-C**. Early case capture of pediatric and young adult cancers: considerations for future rapid case ascertainment studies. Oral presentation at NAACCR 2019 Annual Conference. Vancouver, BC, Canada, June 12, 2019.
 71. Pollack L, Thompson T, Christopher J, Wu X, Rees J, Rycroft R, **Hsieh M-C**, Wilson R, Freeman MB, Zhang K, Benard V, Wu M. Tracking recurrence in population-based cancer surveillance: Where to start? Literally! Oral presentation at NAACCR 2019 Annual Conference. Vancouver, BC, Canada, June 13, 2019
 72. Thompson T, Pollack L, Christopher J, Wu X, Rees J, Rycroft R, **Hsieh M-C**, Wilson R, Freeman MB, Zhang K, Benard V, Wu M. Defining cancer recurrence in a population-based cancer surveillance study. Oral presentation at NAACCR 2019 Annual Conference. Vancouver, BC, Canada, June 13, 2019
 73. Wu XC, Lynch MA, Bao L, Zhou M, **Hsieh M**, Kalitz J. Utilization of microsatellite instability testing and associated factors among colorectal cancer patients. Oral presentation at NAACCR 2019 Annual Conference. Vancouver, BC, Canada, June 13, 2019
 74. Greek A, Jackson E, **Hsieh M**, Alverson G, Crosbie A, Stroup AM, Benard VB. Medical chart review for screening history among women with invasive cervical cancer in three states: CICC Study, 2013-2016. Oral presentation at NAACCR 2019 Annual Conference. Vancouver, BC, Canada, June 13, 2019
 75. Chu QD, **Hsieh M-C**, Chu YD, Wu X-C. Breast cancer Mortality for elderly Women with Breast cancer is Highest at Community Cancer Center Compared to Comprehensive

- Community Cancer Program and Academic Research Program. Presented at Louisiana Chapter American College of Surgeons, New Orleans, LA. January 18, 2020.
76. Chu QD, Chu YD, **Hsieh M-C**, Lagraff T, Zibari GB, Shokouh-Amiri H, Gibbs JF, Tan T-W, Wu X-C. Treatment at a High Volume Academic Research Program Mitigates Racial/Ethnic Disparities in Pancreatic Adenocarcinoma. Presented at Louisiana Chapter American College of Surgeons, New Orleans, LA. January 19, 2020.
 77. Chu QD, Chu YD, **Hsieh M-C**, Lagraff T, Zibari GB, Shokouh-Amiri H, Gibbs JF, Tan T-W, Wu X-C. Rural Residence Does Not Predict Outcome for Resected Pancreatic Adenocarcinoma. Poster presentation at Louisiana Chapter American College of Surgeons, New Orleans, LA. January 17-19, 2020
 78. Chu QD, **Hsieh M-C**, Chu Y, Lagraff T, Wu X-C. Higher Breast Cancer Mortality at Community Center. Presented at the 15th Annual Academic Surgical Congress. Orlando, FL. February 4-6, 2020. Abstract #:ASC20200336.
 79. Chu QD, **Hsieh M-C**, Tan T-W, Chu Y, Lagraff T, Lyons J, Kandil E, Corsetti R, Gnerlich JL, Wu X-C. Operable Breast Cancer Mortality in Rural Louisiana: Results of the Louisiana Cancer Consortium. QuickShot Presentation at the 15th Annual Academic Surgical Congress, Orlando, FL. February 4-6, 2020. Abstract #: ASC20200229.
 80. Zhang Y, Simoff MJ, Ost D, Wagner O, Lavin J, Nauman E, **Hsieh M-C**, Wu XC, Shi L. Lung cancer patient characteristics from a data linkage study. Poster presentation at ISPOR 2020, Orlando, FL. May 18, 2020, Poster# PCN226.
 81. Zhang Y, Simoff MJ, Ost D, Wagner O, Lavin J, Nauman E, **Hsieh M-C**, Wu XC, Shi L. Follow-up of Patients with SPN and No Evidence of Lung cancer: A Data Linkage Study. Poster presentation at ISPOR 2020, Orlando, FL. May 18, 2020, Poster# PCN237.
 82. Zhang Y, Simoff MJ, Ost D, Wagner O, Lavin J, Nauman E, **Hsieh M-C**, Wu XC, Shi L. Date linkage between Tumor Registry and Electronic Medical Record for patient Journey study in lung cancer. Poster presentation at ISPOR 2020, Orlando, FL. May 18, 2020, Poster# PCN349.
 83. **Hsieh M**, Wu X, Kruchko C, Qiao B, Ostrom Q, Sineshaw H, Wu M, Huang B, Sherman R. Evaluating Types of Diagnostic Confirmation and Unknown Rate between Benign/Borderline and Malignant Brain Tumors among Central Cancer Registries in the United States. Poster presentation at NAACCR 2020 virtual conference, June 23-25, 2020.
 84. Lefante CM, **Hsieh M-C**, Gomez N, Wu X-C. Best Practices for Collecting Timely CIN-3 Data in a Central Cancer Registry Setting. NAACCR 2020 annual conference.
 85. Wu X-C, Lynch MA, Mi W, Mumphrey B, Yi Y, **Hsieh M**, Karlitz J. Trends of MSI/IHC Testing, Sociodemographic Disparities in Its Utilization, and Percentage of Positive Results among Colorectal Cancer Patients. NAACCR 2020 annual conference.
 86. Yi Y, Maniscalco LS, **Hsieh M**, Wu X-C. Consistencies between the usual body weight and body weight collected by population-based cancer registry. NAACCR 2020 annual conference.
 87. Zhang L, **Hsieh M-C**, Neroda P, Wu X-C, Wu J, Hicks C, Rennert L, Gimbel R. Timely treatment and survival for localized lung cancer. Poster presentation at IASLC 2020 North American Conference on Lung Cancer virtual meeting on October 16-17, 2020.

88. Neroda P, **Hsieh M-C**, Wu X-C, Cartmell K, Mayo R, Wu J, Hicks C, Zhang L. Racial disparity in the timely treatment of non-small cell lung cancer. Poster presentation at IASLC 2020 North American Conference on Lung Cancer virtual meeting on October 16-17, 2020.
89. Kao Y-H, **Hsieh M-C**, Wu X-C, Tseng T-S. Cigarette smoking and cancer-specific mortality in tobacco-related and non-tobacco related cancer survivors. Poster presentation at the APHA 2020 virtual annual meeting & Expo. October 24-28, 2020.
90. Chu QD, **Hsieh M-C**, Lyons J, Wu X-C. 10-Year Survival after Breast-Conserving Surgery is better than Mastectomy for Louisiana Women with Early Breast Cancer: A Population-Based Study. Abstract #30. Southern Surgical Association Annual Scientific Program 2020
91. Loch M, **Hsieh MC**, Wu XC, and Chen VW. Triple negative breast cancer in New Orleans. Poster presentation at the 2020 San Antonio Breast Cancer Symposium®, December 8-12, 2020.
92. Kao Y-H, **Hsieh M-C**, Wu X-C, Tseng T-S. Association between smoking status and late-stage diagnosis of breast cancer. Post presentation at the Society of Epidemiology Research (SER) 2020 Virtual conference, December 16-18, 2020.
93. Jetly R, Li T, **Hsieh M-C**, Mumphrey B, Wu X-C. Impact of WHO-2017 Guidelines and Sociodemographic Factors on Pathology Evaluation of Diffuse Large B-Cell Lymphomas in Louisiana. Post presentation at United States and Canadian Academy of Pathology (USCAP) 2021 Annual Meeting, March 13-18, 2021.
94. Zhang Y, **Hsieh M-C**, Nauman B, Callison K, Tackett S, Shi L. Risk Factors of Treatment Delay Among NON-SMALL Cell Lung Cancer (NSCLC) Patients in Louisiana. Research Abstract for Virtual ISPOR 2021 conference, May 17-20, 2021
95. Zhang Y, **Hsieh M-C**, Nauman B, Callison K, Tackett S, Shi L. Treatment Delay of Non-Small Cell Lung Cancer (NSCLC) in Louisiana. Poster presentation at AcademyHealth 2021 Annual Research Meeting, June 14-17, 2021.
96. **Hsieh M-C**, Zhang L, Velasco-Gonzalez C, Yi Y, Pareti LA, Trapido E, Chen VW, Wu X-C. Do Modifiable Risk Factors Impact Pancreatic Cancer Survival in a Population-based Study after Adjusting for Clinical Factors? Virtual poster presentation at NAACCR Summer Forum 2021. June 15-17, 2021. **Received the 2nd Place Poster Award.**
97. Wu X-C, Yi Y, **Hsieh M-C**, Lyons J, Chu QD. Lower 10-year survival among total mastectomy recipients than recipients of breast-conserving surgery plus radiation among early-stage breast cancer patients. Presented at NAACCR Summer Forum 2021. June 15-17, 2021.
98. Chu QD, Yi Y, **Hsieh M-C**, Lyons J, Wu X-C. Breast-conserving surgery plus radiation yielded better outcomes than mastectomy for all subtypes of early-stage breast cancer. Analysis of over 200,000 women. Oral presentation at Southern Surgical 2021 conference, December 5-8, 2021 in Hot Springs, Virginia. Abstract# 368.
99. Li T, **Hsieh M**, McDaniel LS, Peters E. The impact of environmental quality on colorectal cancer incidence rates in the United States. Poster presentation at AACR Virtual Conference: 14th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved. October 6-8, 2021.

100. Candal R, Li T , **Hsieh M**, Yi Y, Gibbs JF, Wu X, Chu QD. Survival Paradox between Stage IIB/C and Stage IIIA Colon Cancer. Presented at the 2022 Academic Surgical Congress on Feb 1-3, 2022, Orlando, FL. Abstract ID: ASC20220709.
101. Wu X-C, Yi Y, Maniscalco L, **Hsieh M-C**, Gruber D, Mendoza L, Sokol T, Moderos ET, Ochoa A. Racial Disparity in COVID-19 Severity after Adjusting for Chronic Illnesses and Sociodemographic Factors. Oral presentation at AACR Annual Meeting 2022. April 8-13, 2022, New Orleans, LA.
102. Tanaka T, Lynch C, Yu K, Morawski B, **Hsieh M-C**, Alverson G, Zimmerman H, Austin AI, Zeng Y and Engels EA. Pancreatic cancer among solid organ transplant recipients in the United States. Poster Presentation at 2022 Digestive Disease Week, May 22, 2022.
103. Stewart N, **Hsieh M-C**, Shoup M, Arnoletti JP, Wu X-C, Chu QD. Is Adjuvant Chemotherapy Necessary for Stage I Appendiceal Adenocarcinoma? Oral presentation at Florida Chapter - ACS 2022 Annual meeting on May 14, 2022, Tampa, FL
104. Palm PH, **Hsieh M-C**, Shoup M, Arnoletti JP, Wu X-C, Chu QD. Is Adjuvant Chemotherapy Necessary for Stage IIB/IIC Appendiceal Adenocarcinoma? Submitted to ACS in May 2022.
105. **Hsieh M-C**, Lefante T, Yi Y, Wu X-C. Racial/Ethnic Disparities in COVID-19 Infection among Working-Age Women with Precancerous Cervical Lesion. Poster presentation at NAACCR 2022 Summer Forum, June 14-16, 2022. **Received the 2nd Place Poster Award.**
106. Johnson C, Morawski B, **Hsieh M-C**, Wu M, Mariotto A, Sherman R. Assessing central registry fitness-for-use of cause of death data for cause-specific survival. Presented at NAACCR 2022 Summer Forum. June 14-16, 2022.
107. Wu X-C, Yi Y, Maniscalco L, **Hsieh M-C**, Shrestha P, Chen VM, Gruber A, Mendoza L, Sokol T, Mederos ET, Ochoa A. Racial Disparity in COVID-19 Related Hospital Admission among Breast Cancer Patients. Presented at *NAACCR 2022 Summer Forum, June 14, 2022.*
108. Shrestha P, **Hsieh M-C**, Yi Y, Wu X-C. Factors associated with increased COVID-19 deaths among COVID-19 prostate cancer patients varied by race. Poster presentation at NAACCR 2022 Summer Forum, June 14-16, 2022.
109. Li T, Rung AL, KC M, **Hsieh M-C**, LS Rozek, Peters ES. The effect of neighborhood deprivation on colon cancer patients in Louisiana: A multilevel study. Poster presentation at 15th AACR Conference on The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved - American Association for Cancer Research (AACR) on September 16-19, 2022. Philadelphia, PA
110. Laughlin A, Li T, Yu Q, Wu X, Yi Y, **Hsieh M-C**, Shoup M, Chu Q. Impact of Medicaid Expansion on Breast Cancer Diagnosis and Treatment in Southern States. Presented at the 2022 Annual Meeting of the Southern Surgical Association. December 4-7, 2022, Palm Beach, FL
111. Zhao Y, Sun L, **Hsieh M**, Jamero D, Shi L. Racial Disparity in Treatment among Louisiana Work-Age Survivors with Breast Cancer. Poster Presentation at XULA 16th Health Disparities Conference. February 22-24, 2023, New Orleans, LA.
112. Venkatesh H, Laughlin A, Li T, Yu Q, Wu XC, Yi Y, **Hsieh MC**, Shoup M, Chu QD. ACA Expansion Increases Access for Black, Rural Patients with Pancreatic Cancer in Southern States. Poster Presentation at AHPBA 2023 conference, March 9 – 12, 2023, Miami, FL

113. Gaffley M, Li T, **Hsieh M-C**, Yi Y, Gibbs J, Wu X-C, Gallagher J, Chu QD. Rural versus urban commuting patients with Stage III Colon Cancer: Is there a difference in treatment and outcome? Oral presentation at SAGES 2023 Annual Meeting, Montréal, QC Canada, March 29-April1, 2023.
114. Escott M, Li T, **Hsieh M-C**, Delacroix Jr. S, Gills J, Wu X-C, Westerman M. The impact of rural residency on the treatment and outcomes of locally invasive/advanced bladder cancer in Louisiana. Post Presentation at American Urological Association Annual Meeting 2023. Chicago IL, April 28, 2023. *The Journal of Urology*. 2023;209(4S).
115. Zhao Y, Sun L, **Hsieh M**, Jamero D, Shi L. Racial/Ethnic Disparity in Follow-up Care among Work-Age Female Breast Cancer Survivors in Louisiana: Preliminary Results. Poster presentation at ISPOR 2023, May 7 - 10, 2023.
116. **Hsieh M-C**, Sherman R. The Data Quality of Race_1 Field, Issues and Implications. Oral presentation at NCRA 49th Annual Educational Conference. San Diego, CA, May 10, 2023.
117. Zwald F, Yu K, Austin A, **Hsieh M**, Pawlish K, Li J, Lynch C, Sargen M, Engels E. melanoma-Specific Mortality in Patients with Pre-transplant melanoma. Poster presentation at American Transplant Congress, San Diego, CA, June 3-7, 2023.
118. Wu XC, Yu QZ, Yi Y, Maniscalco LS, **Hsieh MC**, Chen VW, Ochoa A. Effect of Underlying Health Conditions on Racial Difference in COVID-19 Hospitalization among Cancer Patients. Presented at the NAACCR 2023 Annual Conference, New Orleans, LA. June 20, 2023.
119. Ratnapradipa KL, Li T, **Hsieh M-C**, Peters ES. People living in the most vs. least disadvantaged areas have higher liver cancer incidence and worse survival. Oral presentation at San Antonio Liver Cancer Symposium on October 20th, 2023.
120. Venkatesh H, Laughlin A, Li T, Yu Q, Wu XC, Yi Y, **Hsieh MC**, Shoup M, Chu QD. Medicaid Expansion Increases Treatment for Rural and Impoverished Patients with Pancreatic Cancer in Southern States. Oral presentation in the Scientific Forum at Clinical Congress 2023: October 22-25, 2023, in Boston, MA.
121. Henry V, Stephens MJ, Ariotti A, **Hsieh M-C**, Yi Y, Muhsen R, Engels E, Watt MH, Bartlett J, Ubel P, Fagerlin A, Suneja G. Treatment Decision-Making among Physicians Treating People Living with HIV and Cancer: A Registry-Linked Survey Study. Poster presentation at Society for Medical Decision Making (SMDM) 45th annual North American meeting on October 22-25, 2023, Philadelphia, PA.
122. Maramara T, Janjua M, **Hsieh M-C**, Li T, Wu X-C, Williams M, Shoup M, Chu QD. Adherence rate to ACOSOG Z0011 based on breast cancer subtypes. Present at the Southern Surgical Association 2023 (135th) Annual Meeting. December 3-6, 2023. Homestead in Hot Springs, VA.
123. Stewart JH, **Hsieh M-C**, Maniscalco L, Yi Y, Wu X-C, McKinney S, Chu QD. An Analysis of Breast Conservation Therapy in Patients with Early-Stage Breast Cancer in Louisiana. Present at the Southern Surgical Association 2023 (135th) Annual Meeting. December 3-6, 2023, Homestead in Hot Springs, VA.
124. Mabvakure B, Li S, Delgado-Herrera DC, **Hsieh M**, Benjamin W, Martinez-Cruz L, Patil S, Mohebbi E, D'Silva N, Sartor MA, Rozek LS. Comparison of HPV Virus-Induced Oropharyngeal Cancer by Self-Reported Race and the Potential Implications on Treatment. AACR Annual Meeting 2024. April 5-10, 2024. San Diego, CA.

125. Zwald F, Sargen M, Austin A, **Hsieh M-C**, Pawlish K, Li J, Lynch CF, Yu K, Engels E. Outcomes in solid organ transplant recipients with a pretransplant diagnosis of melanoma. American Transplant Congress 2024. June 1-5, 2024. Philadelphia, PA.
126. Prusisz T, Run AL, **Hsieh M-C**, Oral E, Trapido EJ, Levitzky E, Peters ES. No Elevated Risk of Cancer in Women of Southeastern Louisiana 12 Years after the Deepwater Horizon Oil Spill. Poster presentation at 2024 Society for Epidemiological Research (SER) Meeting June 18-21, 2024. Austin, TX.
- 127.** Tao J, Shing JZ, Yu K, Kreimer AR, **Hsieh M-C**, Pawlish K, Li J, Qiao B, Engels EA. Spectrum of cancer risk in Asian American, Native Hawaiian, and other Pacific Islander Populations After Solid Organ Transplantation in the United States in the US. Society for Epidemiological Research Meeting. Austin, TX. Jun 18-21, 2024.
128. Wu X-C, Yi Y, Maniscalco LS, **Hsieh M-C**. HIV Elevates Cancer Mortality Risk More in AIDS-Defining Malignancies than Non-ADM Cases. NAACCR 2024 conference. Boise, ID. June 25-27, 2024.
129. Northup S, Wendell D, **Hsieh M**, Albright M, Nakouzi T, De La Rosa E, Mandani J. Analyzing pre-exposure prophylaxis (PrEP) persistence: Insights to Louisiana's teleprep program. **Presented at APHA's 2024 Annual Meeting & Expo**. October 27-30, 2024. Minneapolis, MN.
130. Rozek L, Purrington K, Patil S, **Hsieh M-C**, Stoffel E. Survival Differences between Early Onset (< 50 years) and Average Onset (≥ 50 years) Colorectal Cancer among African Americans in Metropolitan Detroit. American Society of Preventive Oncology (ASPO) 2025 Annual Conference, April 6-8, 2025, in Philadelphia, PA.
131. Lawas MC, **Hsieh M-C**, Patil S, Duttargi A, Kulahreshtha A, Cruz LM, Garb B, Li S, D'Silva N, Sartor M, Rozek L. p16 predictiveness for HPV-associated head and neck cancer in African Americans compared to Non-Hispanic Whites. Poster presentation at AACR Annual Meeting 2025; April 25-30, 2025; Chico, IL. Cancer Res (2025) 85 (8_Supplement_1): 7103. <https://doi.org/10.1158/1538-7445.AM2025-7103>.
132. **Hsieh M-C**, Stoffel E, Wu X-C, Purrington K, Mabvakure B, Rozek L. Racial and Anatomical Tumor Site disparities in Colorectal Cancer Survival stratified by Early- and Late-Onset Patients. Oral presentation at NAACCR 2025 conference, Hartford, CT. June 3-5, 2025.
133. Wu X-C, Yi Y, Yu Q, Maniscalco L, **Hsieh M-C**, Kinchen JW, Moaven O, Lyons JM. Trapido E. Survival Differences in Hepatocellular Carcinoma Patients with and without Hepatitis C Virus Infection: A Comparative Analysis Adjusting for Socio-Demographic and Clinical Factors. Oral presentation at NAACCR 2025 conference, Hartford, CT. June 3-5, 2025.
134. Lawas MC, **Hsieh M-C**, Patil S, Elham M, Mabvakure B, Dutteraji A, Cruz LM, Garb B, Li S, D'Silva NJ, Sartor M, Rozek L. Racial disparities and role of HPV in oropharyngeal cancer in two US populations. Poster presentation at the 2025 Advances in Genome Biology and Technology (AGBT) Precision Health Meeting. September 8-10, 2025, San Diego, CA
- 135.** Venkatesh H, **Hsieh M-C**, Jyons J, Wu X-C, Chu Q. Is adjuvant chemotherapy necessary for stage IIB/IIC appendiceal adenocarcinoma? Oral presentation at Southeastern Surgical Congress (SESC) 2026. February 20-23, 2026. Omni Amelia Island, FL. **Received the 2026 SESC Foundation Young Investigator Award as the most promising research.**
136. Lima SM, Dash C, Patil S, Ahn J, Zhang R, Promprasert C, Mabvakure B, Muhsen R, Schwartz A, Ruterbach J, Wenzlaff A, Peluso A, Stoffel E, **Hsieh M-C**, Purrington KS, Rozek

- L. Investigating greenspace and recreational spaces as modifiers of physical activity on colorectal cancer survival. Poster presentation at American Society for Preventive Oncology (ASPO) Annual Meeting 2026. April 12-14, 2026, Denver CO.
137. Luo Q, **Hsieh M-C**, Zeng Y, Lynch CF, Morawski B, Moreno A, Wang S, Pfeiffer RM, Engels EA. Cancer burden among solid organ transplant recipients in the United States, 2009–2019. American Transplant Congress 2026. June 20-24, 2026, Boston, MA
138. Tseng Y-H, Tseng Y-C, Lin Y-H, Chen Y-M, **Hsieh M-C**. Real-World Utilization and Survival Trends of Adjuvant Immunotherapy in Postoperative NSCLC: A Louisiana Population-Based Study. **Submitted to 2026 ASCO Annual Meeting on January 25, 2026. May 29-June 2, 2026. Chicago, IL.**

Invited Speaker/Instructor:

- **2009 International Conference on Cancer Registry (ICCR), September 19-20, 2009, Taipei, Taiwan**
 - *Facility Oncology Registry Data Standards (FORDS): Revised for 2009 and 2010 Changes*
 - *Multiple Primary and Histology Coding Rules*
- **2012 National Cancer Registrars Association (NCRA), April 21st, 2012, National Harbor, MD.**
“E-Path: The Next Frontier in Registry Operation – Louisiana’s Experience
- **7th General Assembly and International Conference of Asian Pacific Organization for Cancer Prevention. March 20-23, 2014, Academia Sinica, Taipei, Taiwan.**
 - *An Introduction of ICD-10-CM for the Taiwan Cancer Registry*
 - *Electronic Health Record and Health Information Exchange Affect cancer Registry Operation*
- **Taiwan Society of Cancer Registry Train the Trainer Workshop, March 22, 2014. Taiwan National University, Taipei, Taiwan.**
 - *2014 updates on hematopoietic and lymphoid neoplasm database and coding manual*
 - *New instructions for coding grade*
 - *Highlights of 2015 solid tumor database and manual*
 - *CTR exam in the United States*
 - *Coding scope of regional lymph node surgery*
- **SEER 2015 Workshop – Advanced Topics for Registry Professionals. May 19-20, 2015. San Antonio, TX**
 - *New 2014 Grade Coding Rules*
- **Taiwan Society of Cancer Registry Train the Trainer Workshop, Tai-Chung, Taiwan, June 23-24, 2018.**
 - *Site-Specific Data Items (SSDIs)*

- *Extent of Disease (EOD) 2018 and Summary Stage 2018*
- *Collaborative Staging (CS) to EOD Schema: Using SEER Registrar Staging Assistant (SEER*RSA)*
- *2018 Grade Coding Rules*
- *Use of Cancer Registry Data*
- **2019 International Conference on Cancer Registry (ICCR), October 18-19, 2019, Taipei, Taiwan**
 - AI and Cancer Registry in the United States: Current Progress, Future Advances, and Implementation of AI-Based Cancer Registry
 - Collecting and Coding Recurrence Data and Its Utilization in the United States
- **NAACCR virtual workshop - Using Linkages to Enhance Cancer Registry Operations , May 18, 2021**
 - Requesting Annual Hospital Re-transmit of Cases to Improve Cancer Data Completeness: A 15-Month Data Submission
- **SEER Quality Improvement Experts (QIE) meeting, October 11, 2022**
 - Using External Data Sources to Enhance Cancer Data Quality: LTR's Experiences
- **SEER Quality Improvement Experts (QIE) meeting, June 10, 2025**
 - Evaluating SEER SSF1 – HPV Testing: A Pilot QC Project

Presentations at Louisiana Cancer Registrars Association (LCRA) Conference:

- *"LTR Major Data Submissions and Deadlines"*, LCRA Spring conference, March 15-16, 2004.
- *"SEER Data Quality Profiles"*, LCRA Spring conference, March 16-17, 2006.
- *"Race Codes for Asian and Pacific Islander"* LCRA Fall conference, October 17-19, Lafayette, LA. 2007
- *"Important Non-CS 2010 Data Items – New and Revised"* LCRA Fall conference, Lafayette, LA. November 11-12, 2010
- *"Data Processing in the Louisiana Tumor Registry"* LCRA Spring conference, Baton Rouge, LA. April 14-15, 2011
- *"Required New Variables for CDC-NPCR CER Specialized Registry"* LCRA Spring conference, April 14-15, 2011
- *"Identifying CS Coding Inconsistency Issues Using In-house Edits"* LCRA Fall conference. Lafayette, LA. September 20-21, 2012
- *"Award for the Outstanding Hospital Registries – LTR DQI Report"* LCRA Fall conference. Baton Rouge, LA. October 17-18, 2013
- *"Innovative Method to Improve the Completeness of Benign/Borderline Brain/CNS Tumor"* LCRA Annual conference. Lafayette, LA. October 17, 2014.

- “Certification Awards for Outstanding Hospital Registries”, LCRA Annual conference, Baton Rouge, LA. October 15-16, 2015
- “LTR Data Quality-Reabstraction Audit Results”, LCRA 2017 Annual Conference, Shreveport, LA. October 12-13, 2017.
- “2018 Grade Coding Rules” LCRA 2018 Annual Conference, Baton Rouge, LA. October 19, 2018.
- “LTR Casefinding Audits Results: Why Cases Are Missed?” LCRA 2019 Annual Conference, Lafayette, LA. September 13, 2019.

RESEARCH ARTICLE AND APPLICATION REVIEWS

Journal Reviewer:

- Journal of Adolescent and Young Adult Oncology
- Journal of Open Research Software
- Scientific Reports
- Journal of the Royal Statistical Society
- Colorectal Cancer
- Statistics in Medicine
- Annals of Epidemiology
- BMC Cancer
- BMC Public Health
- JNCCN
- The American Journal of Managed Care
- British Journal of Cancer
- Journal of Geriatric Oncology
- ESMO (European Society for Medical Oncology) open
- Clinical Breast Cancer
- PLOS Global Public Health
- Cancer Management and Research
- Ethnicity & Health
- Cancer
- Frontiers in Oncology
- Heliyon
- Cancer Cause & Control
- International Journal of Endocrinology
- Cancer Medicine
- The Egyptian Journal of Bronchology
- Cancers
- Medical care

North American Association of Central Cancer Registries (NAACCR) Research Application Review:

I serve as a member of NAACCR Research Application Review Workgroup and review the applications for using the NAACCR CiNA data.

- 2015 - present

NAACCR IRB Publication Review:

I serve as a member of NAACCR IRB committee and review NAACCR IRB applications and publications that used the NAACCR CINA Deluxe analytic data to ensure researcher complying with the IRB assurances and NAACCR confidentiality rules.

- 2017-present

NAACCR VPR Research Review Committee

- 2018-present

SEER-Medicare Linkage Data Application Review:

- 2019 - present

Abstract Reviewer for Professional Conference

- NAACCR Annual Conference: 2015 - present

Moderator of Conference:

- North American Association of Central Cancer Registries (NAACCR) 2016 Annual Conference: Student oral presentations, St. Louis, MO, June 14, 2016.

NAACCR International Fellows Mentor: June 10, 2019

Judge of Research Presentations:

- NAACCR 2016 Annual Conference: Student Poster Presentations. St. Louis, MO, June 14-16, 2016.
- NAACCR 2017 Annual Conference: Student Poster Presentations. Albuquerque, NM, June 20-22, 2017.
- NAACCR 2018 Annual Conference: Student Poster Presentations. Pittsburg, PA, June 12-14, 2018.
- NAACCR 2019 Annual Conference: Student Poster Presentations. Vancouver, BC, Canada, June 11-13, 2019.
- LSUHSC 2019 Summer Research Internship Program Poster Session. New Orleans, LA. July 26, 2019